SUSANHILSENBECKSUSAN HILSENBECK0.000000000000000.000000000000003634HILSENBECK, SUSANDr. Hilsenbeck has a PhD in applied biostatistics, and has long-standing interests in biostatistical and informatics collaboration, especially in cancer research. She is the statistician of record on a number of investigator initiated multi-center clinical trials leads several of the biostatistics and informatics focused resources at Baylor, including: 1) Biostatistics and Informatics Shared Resource in the Duncan Cancer Center; 2) Biostatistics in the Duncan Institute for Clinical and Translational Research.
Dr. Hilsenbeck's personal research interests focus on design and analysis of prognostic and predictive biomarkers studies. She is also committed to teaching. She serves on mentoring committees, leads the biostatistics course for TBMM graduate students (elective to satisfy biostatistics training requirement for other programs), and is regularly invited to teach in national and international workshops.Professorplugins:TwitterTwitterprns:awardConferredByaward conferred byprns:coAuthorOfcoauthor ofprns:endDateend dateFaculty Rankprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasFacultyRankhas faculty rankprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:mainImagephotoprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:physicalNeighborOfphysical neighborprns:pluginSearchableDataProfilesRNS Plugin Searchable Dataprns:positionInDepartmentposition in departmentprns:positionInDivisionposition in divisionprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:similarTosimilar toprns:sortOrdersort orderprns:startDatestart dateprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierAddressvivo:address1address line 1vivo:addressCitycityvivo:addressPostalCodepostal codevivo:addressStatestate or provincevivo:authorInAuthorshipselected publicationsvivo:authorRankauthor rank in publicationAuthorshipvivo:awardOrHonorawards and honorsAward or Honor ReceiptDepartmentDivisionvivo:hasResearchArearesearch areasvivo:hrJobTitleHR job titleInformation Resourcevivo:linkedAuthorlinked authorvivo:linkedInformationResourcelinked information resourcevivo:mailingAddressmailing addressvivo:overviewoverviewvivo:personInPositionpositionsPositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlerdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPerson25453754Karlin KL, Mondal G, Hartman JK, Tyagi S, Kurley SJ, Bland CS, Hsu TY, Renwick A, Fang JE, Migliaccio I, Callaway C, Nair A, Dominguez-Vidana R, Nguyen DX, Osborne CK, Schiff R, Yu-Lee LY, Jung SY, Edwards DP, Hilsenbeck SG, Rosen JM, Zhang XH, Shaw CA, Couch FJ, Westbrook TFCell reportsThe oncogenic STP axis promotes triple-negative breast cancer via degradation of the REST tumor suppressor. Cell Rep. 2014 Nov 20; 9(4):1318-32.Cell Rep2014-11-06T00:00:002014The oncogenic STP axis promotes triple-negative breast cancer via degradation of the REST tumor suppressor.25489091He B, Lanz RB, Fiskus W, Geng C, Yi P, Hartig SM, Rajapakshe K, Shou J, Wei L, Shah SS, Foley C, Chew SA, Eedunuri VK, Bedoya DJ, Feng Q, Minami T, Mitsiades CS, Frolov A, Weigel NL, Hilsenbeck SG, Rosen DG, Palzkill T, Ittmann MM, Song Y, Coarfa C, O'Malley BW, Mitsiades NProceedings of the National Academy of Sciences of the United States of AmericaGATA2 facilitates steroid receptor coactivator recruitment to the androgen receptor complex. Proc Natl Acad Sci U S A. 2014 Dec 23; 111(51):18261-6.Proc Natl Acad Sci U S A2014-12-08T00:00:002014GATA2 facilitates steroid receptor coactivator recruitment to the androgen receptor complex.Authorship 789895Authorship 8152423Authorship 816052Authorship 8016611Authorship 821322Authorship 834262Authorship 842566Authorship 877262Authorship 881315Authorship 867716Authorship 868591Authorship 8975519Authorship 877502Authorship 877888Authorship 891538Authorship 914799Authorship 932936Authorship 913303Authorship 918926Authorship 945079Authorship 945443Authorship 925045Authorship 948915Authorship 95667Authorship 960674Authorship 965162Authorship 972321Authorship 975743Authorship 969011Authorship 972555Authorship 975625Authorship 976068Authorship 976332Authorship 1011794Authorship 1032895Authorship 1051286Authorship 1085365Authorship 109779Authorship 1112322Authorship 1126423Authorship 1162664Authorship 1180223Authorship 1194745Authorship 1210473Authorship 155406Authorship 155437Authorship 181697Authorship 2504712Authorship 16097915Authorship 1619059Authorship 162561525572662Giuliano M, Herrera S, Christiny P, Shaw C, Creighton CJ, Mitchell T, Bhat R, Zhang X, Mao S, Dobrolecki LE, Al-rawi A, Chen F, Veneziani BM, Zhang XH, Hilsenbeck SG, Contreras A, Gutierrez C, Jeselsohn RM, Rimawi MF, Osborne CK, Lewis MT, Schiff R, Trivedi MVBreast cancer research : BCRCirculating and disseminated tumor cells from breast cancer patient-derived xenograft-bearing mice as a novel model to study metastasis. Breast Cancer Res. 2015 Jan 09; 17:3.Breast Cancer Res2015-01-09T00:00:002015Circulating and disseminated tumor cells from breast cancer patient-derived xenograft-bearing mice as a novel model to study metastasis.25635772Holloway KR, Sinha VC, Toneff MJ, Bu W, Hilsenbeck SG, Li YPloS oneKrt6a-positive mammary epithelial progenitors are not at increased vulnerability to tumorigenesis initiated by ErbB2. PLoS One. 2015; 10(1):e0117239.PLoS One2015-01-30T00:00:002015Krt6a-positive mammary epithelial progenitors are not at increased vulnerability to tumorigenesis initiated by ErbB2.25774287Suo J, Medina D, Herrera S, Zheng ZY, Jin L, Chamness GC, Contreras A, Gutierrez C, Hilsenbeck S, Umar A, Foekens JA, Hanash S, Schiff R, Zhang XH, Chang ECCell & bioscienceInt6 reduction activates stromal fibroblasts to enhance transforming activity in breast epithelial cells. Cell Biosci. 2015; 5:10.Cell Biosci2015-03-08T00:00:002015Int6 reduction activates stromal fibroblasts to enhance transforming activity in breast epithelial cells.Authorship 278382Authorship 163114725735774Zhang M, Tsimelzon A, Chang CH, Fan C, Wolff A, Perou CM, Hilsenbeck SG, Rosen JMCancer discoveryIntratumoral heterogeneity in a Trp53-null mouse model of human breast cancer. Cancer Discov. 2015 May; 5(5):520-33.Cancer Discov2015-03-03T00:00:002015Intratumoral heterogeneity in a Trp53-null mouse model of human breast cancer.Authorship 363108Authorship 402578Investigational Cancer TherapeuticsLeukemiaMolecular & Cellular OncologySystems BiologyMD AndersonMIEN-CHIEHUNGMIEN-CHIE HUNG8427HUNG, MIEN-CHIEProfessorHAGOP MKANTARJIANHAGOP M KANTARJIAN8501KANTARJIAN, HAGOP MProfessorKELLY KHUNTKELLY K HUNT8555HUNT, KELLY KProfessorGORDON BMILLSGORDON B MILLS8620MILLS, GORDON BProfessorFUNDAMERIC-BERNSTAMFUNDA MERIC-BERNSTAM8778MERIC-BERNSTAM, FUNDAProfessorAuthorship 412187Authorship 416053Authorship 452233Authorship 477505Authorship 481732Authorship 503177Authorship 504001Authorship 506824Authorship 511955Authorship 262105525972242Ayala G, Frolov A, Chatterjee D, He D, Hilsenbeck S, Ittmann MEndocrine-related cancerExpression of ERG protein in prostate cancer: variability and biological correlates. Endocr Relat Cancer. 2015 Jun; 22(3):277-87.Endocr Relat Cancer2015-06-01T00:00:002015Expression of ERG protein in prostate cancer: variability and biological correlates.Authorship 545172Authorship 562066Authorship 568533Authorship 60003Authorship 623542Authorship 631144Authorship 632669Authorship 674127Authorship 681807Authorship 693403Authorship 69918Authorship 720567Authorship 763673Authorship 8143410Authorship 8531010Authorship 858487Authorship 877784Authorship 886816Authorship 900985Authorship 931995Authorship 93606325784290Allen-Rhoades W, Kurenbekova L, Satterfield L, Parikh N, Fuja D, Shuck RL, Rainusso N, Trucco M, Barkauskas DA, Jo E, Ahern C, Hilsenbeck S, Donehower LA, Yustein JTCancer medicineCross-species identification of a plasma microRNA signature for detection, therapeutic monitoring, and prognosis in osteosarcoma. Cancer Med. 2015 Jul; 4(7):977-88.Cancer Med2015-03-17T00:00:002015Cross-species identification of a plasma microRNA signature for detection, therapeutic monitoring, and prognosis in osteosarcoma.Authorship 957193American Statistical Association2011Fellow, American Statistical AssociationAmerican Statistical Association20102008Member, Board of Directors,American Statistical AssociationAuthorship 280102123024799Pitchenik AE, Becker DM, Hilsenbeck SG, Trapido EJCancerCancer among Haitians in Florida. Cancer. 1987 Jan 01; 59(1):184-8.Cancer1987-01-01T00:00:001987Cancer among Haitians in Florida.Authorship 2801763Authorship 28017711Authorship 28017873263545Barnavon Y, Iwaki H, Bash JA, Brettschneider F, Hilsenbeck S, Darnell E, Wallack MKThe Journal of surgical researchTreatment of murine hepatic metastases with vaccinia colon oncolysates and IL-2. J Surg Res. 1988 Dec; 45(6):523-30.J Surg Res1988-12-01T00:00:001988Treatment of murine hepatic metastases with vaccinia colon oncolysates and IL-2.26195710Kim ES, Bernstein D, Hilsenbeck SG, Chung CH, Dicker AP, Ersek JL, Stein S, Khuri FR, Burgess E, Hunt K, Ivy P, Bruinooge SS, Meropol N, Schilsky RLJournal of clinical oncology : official journal of the American Society of Clinical OncologyModernizing Eligibility Criteria for Molecularly Driven Trials. J Clin Oncol. 2015 Sep 01; 33(25):2815-20.J Clin Oncol2015-07-20T00:00:002015Modernizing Eligibility Criteria for Molecularly Driven Trials.26015514Giuliano M, Hu H, Wang YC, Fu X, Nardone A, Herrera S, Mao S, Contreras A, Gutierrez C, Wang T, Hilsenbeck SG, De Angelis C, Wang NJ, Heiser LM, Gray JW, Lopez-Tarruella S, Pavlick AC, Trivedi MV, Chamness GC, Chang JC, Osborne CK, Rimawi MF, Schiff RClinical cancer research : an official journal of the American Association for Cancer ResearchUpregulation of ER Signaling as an Adaptive Mechanism of Cell Survival in HER2-Positive Breast Tumors Treated with Anti-HER2 Therapy. Clin Cancer Res. 2015 Sep 01; 21(17):3995-4003.Clin Cancer Res2015-05-26T00:00:002015Upregulation of ER Signaling as an Adaptive Mechanism of Cell Survival in HER2-Positive Breast Tumors Treated with Anti-HER2 Therapy.25953849Buras ED, Yang L, Saha P, Kim J, Mehta P, Yang Y, Hilsenbeck S, Kojima H, Chen W, Smith CW, Chan LFASEB journal : official publication of the Federation of American Societies for Experimental BiologyProinsulin-producing, hyperglycemia-induced adipose tissue macrophages underlie insulin resistance in high fat-fed diabetic mice. FASEB J. 2015 Aug; 29(8):3537-48.FASEB J2015-05-07T00:00:002015Proinsulin-producing, hyperglycemia-induced adipose tissue macrophages underlie insulin resistance in high fat-fed diabetic mice.3378789Suster S, Hilsenbeck S, Rywlin AMHuman pathologyReactive histiocytic hyperplasia with hemophagocytosis in hematopoietic organs: a reevaluation of the benign hemophagocytic proliferations. Hum Pathol. 1988 Jun; 19(6):705-12.Hum Pathol1988-06-01T00:00:001988Reactive histiocytic hyperplasia with hemophagocytosis in hematopoietic organs: a reevaluation of the benign hemophagocytic proliferations.3180826Hilsenbeck SGControlled clinical trialsEarly termination of a phase II clinical trial. Control Clin Trials. 1988 Sep; 9(3):177-88.Control Clin Trials1988-09-01T00:00:001988Early termination of a phase II clinical trial.7525978Yee D, Sharma J, Hilsenbeck SGJournal of the National Cancer InstitutePrognostic significance of insulin-like growth factor-binding protein expression in axillary lymph node-negative breast cancer. J Natl Cancer Inst. 1994 Dec 07; 86(23):1785-9.J Natl Cancer Inst1994-12-07T00:00:001994Prognostic significance of insulin-like growth factor-binding protein expression in axillary lymph node-negative breast cancer.7814611Takahashi S, Goldring S, Katz M, Hilsenbeck S, Williams R, Roodman GDThe Journal of clinical investigationDownregulation of calcitonin receptor mRNA expression by calcitonin during human osteoclast-like cell differentiation. J Clin Invest. 1995 Jan; 95(1):167-71.J Clin Invest1995-01-01T00:00:001995Downregulation of calcitonin receptor mRNA expression by calcitonin during human osteoclast-like cell differentiation.8007700Hilsenbeck SG, Clark GMJournal of cellular biochemistry. SupplementSurrogate endpoints in chemoprevention of breast cancer: guidelines for evaluation of new biomarkers. J Cell Biochem Suppl. 1993; 17G:205-11.J Cell Biochem Suppl1993-01-01T00:00:001993Surrogate endpoints in chemoprevention of breast cancer: guidelines for evaluation of new biomarkers.6518294Wang G, Vogel CL, Hilsenbeck SG, Voigt W, Thomsen SBreast cancer research and treatmentValue of 8S/4S fractionation of estrogen receptors (ER) for prediction of response to hormonal manipulation in metastatic breast cancer. Breast Cancer Res Treat. 1984; 4(4):283-8.Breast Cancer Res Treat1984-01-01T00:00:001984Value of 8S/4S fractionation of estrogen receptors (ER) for prediction of response to hormonal manipulation in metastatic breast cancer.7512885McGuire SE, Hilsenbeck SG, Figueroa JA, Jackson JG, Yee DCancer lettersDetection of insulin-like growth factor binding proteins (IGFBPs) by ligand blotting in breast cancer tissues. Cancer Lett. 1994 Feb 28; 77(1):25-32.Cancer Lett1994-02-28T00:00:001994Detection of insulin-like growth factor binding proteins (IGFBPs) by ligand blotting in breast cancer tissues.8062191Pujol P, Hilsenbeck SG, Chamness GC, Elledge RMCancerRising levels of estrogen receptor in breast cancer over 2 decades. Cancer. 1994 Sep 01; 74(5):1601-6.Cancer1994-09-01T00:00:001994Rising levels of estrogen receptor in breast cancer over 2 decades.7573366Isola JJ, Kallioniemi OP, Chu LW, Fuqua SA, Hilsenbeck SG, Osborne CK, Waldman FMThe American journal of pathologyGenetic aberrations detected by comparative genomic hybridization predict outcome in node-negative breast cancer. Am J Pathol. 1995 Oct; 147(4):905-11.Am J Pathol1995-10-01T00:00:001995Genetic aberrations detected by comparative genomic hybridization predict outcome in node-negative breast cancer.8098270Choy H, Rodriguez FF, Koester S, Hilsenbeck S, Von Hoff DDCancerInvestigation of taxol as a potential radiation sensitizer. Cancer. 1993 Jun 01; 71(11):3774-8.Cancer1993-06-01T00:00:001993Investigation of taxol as a potential radiation sensitizer.8120545Ravdin PM, Tandon AK, Allred DC, Clark GM, Fuqua SA, Hilsenbeck SH, Chamness GC, Osborne CKJournal of clinical oncology : official journal of the American Society of Clinical OncologyCathepsin D by western blotting and immunohistochemistry: failure to confirm correlations with prognosis in node-negative breast cancer. J Clin Oncol. 1994 Mar; 12(3):467-74.J Clin Oncol1994-03-01T00:00:001994Cathepsin D by western blotting and immunohistochemistry: failure to confirm correlations with prognosis in node-negative breast cancer.7693722Figueroa JA, Sharma J, Jackson JG, McDermott MJ, Hilsenbeck SG, Yee DJournal of cellular physiologyRecombinant insulin-like growth factor binding protein-1 inhibits IGF-I, serum, and estrogen-dependent growth of MCF-7 human breast cancer cells. J Cell Physiol. 1993 Nov; 157(2):229-36.J Cell Physiol1993-11-01T00:00:001993Recombinant insulin-like growth factor binding protein-1 inhibits IGF-I, serum, and estrogen-dependent growth of MCF-7 human breast cancer cells.8194171Osborne CK, Jarman M, McCague R, Coronado EB, Hilsenbeck SG, Wakeling AECancer chemotherapy and pharmacologyThe importance of tamoxifen metabolism in tamoxifen-stimulated breast tumor growth. Cancer Chemother Pharmacol. 1994; 34(2):89-95.Cancer Chemother Pharmacol1994-01-01T00:00:001994The importance of tamoxifen metabolism in tamoxifen-stimulated breast tumor growth.7819588Fuqua SA, Oesterreich S, Hilsenbeck SG, Von Hoff DD, Eckardt J, Osborne CKBreast cancer research and treatmentHeat shock proteins and drug resistance. Breast Cancer Res Treat. 1994; 32(1):67-71.Breast Cancer Res Treat1994-01-01T00:00:001994Heat shock proteins and drug resistance.8324747Bookstein R, MacGrogan D, Hilsenbeck SG, Sharkey F, Allred DCCancer researchp53 is mutated in a subset of advanced-stage prostate cancers. Cancer Res. 1993 Jul 15; 53(14):3369-73.Cancer Res1993-07-15T00:00:001993p53 is mutated in a subset of advanced-stage prostate cancers.8229134Rothenberg ML, Kuhn JG, Burris HA, Nelson J, Eckardt JR, Tristan-Morales M, Hilsenbeck SG, Weiss GR, Smith LS, Rodriguez GIJournal of clinical oncology : official journal of the American Society of Clinical OncologyPhase I and pharmacokinetic trial of weekly CPT-11. J Clin Oncol. 1993 Nov; 11(11):2194-204.J Clin Oncol1993-11-01T00:00:001993Phase I and pharmacokinetic trial of weekly CPT-11.8398345Hanauske AR, Ross M, Degen D, Hilsenbeck SG, Von Hoff DDEuropean journal of cancer (Oxford, England : 1990)In vitro activity of the benzotriazine dioxide SR 4233 against human tumour colony-forming units. Eur J Cancer. 1993; 29A(3):423-5.Eur J Cancer1993-01-01T00:00:001993In vitro activity of the benzotriazine dioxide SR 4233 against human tumour colony-forming units.7563152Osborne CK, Coronado-Heinsohn EB, Hilsenbeck SG, McCue BL, Wakeling AE, McClelland RA, Manning DL, Nicholson RIJournal of the National Cancer InstituteComparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. J Natl Cancer Inst. 1995 May 17; 87(10):746-50.J Natl Cancer Inst1995-05-17T00:00:001995Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer.8634988Sevin BU, Nadji M, Lampe B, Lu Y, Hilsenbeck S, Koechli OR, Averette HECancerPrognostic factors of early stage cervical cancer treated by radical hysterectomy. Cancer. 1995 Nov 15; 76(10 Suppl):1978-86.Cancer1995-11-15T00:00:001995Prognostic factors of early stage cervical cancer treated by radical hysterectomy.Authorship 28126698995913De Boever AL, Keeling SD, Hilsenbeck S, Van Sickels JE, Bays RA, Rugh JDJournal of orofacial painSigns of temporomandibular disorders in patients with horizontal mandibular deficiency. J Orofac Pain. 1996; 10(1):21-7.J Orofac Pain1996-01-01T00:00:001996Signs of temporomandibular disorders in patients with horizontal mandibular deficiency.9131264Diab SG, Yu YY, Hilsenbeck SG, Allred DC, Elledge RMBreast cancer research and treatmentWAF1/CIP1 protein expression in human breast tumors. Breast Cancer Res Treat. 1997 Apr; 43(2):99-103.Breast Cancer Res Treat1997-04-01T00:00:001997WAF1/CIP1 protein expression in human breast tumors.7904173Vogel M, Hilsenbeck SG, Depenbrock H, Danhauser-Riedl S, Block T, Nekarda H, Fellbaum C, Aapro MS, Bissery MC, Rastetter JEuropean journal of cancer (Oxford, England : 1990)Preclinical activity of taxotere (RP 56976, NSC 628503) against freshly explanted clonogenic human tumour cells: comparison with taxol and conventional antineoplastic agents. Eur J Cancer. 1993; 29A(14):2009-14.Eur J Cancer1993-01-01T00:00:001993Preclinical activity of taxotere (RP 56976, NSC 628503) against freshly explanted clonogenic human tumour cells: comparison with taxol and conventional antineoplastic agents.1290800Hilsenbeck SG, Kurucz C, Duncan RCBiometricsEstimation of completeness and adjustment of age-specific and age-standardized incidence rates. Biometrics. 1992 Dec; 48(4):1249-62.Biometrics1992-12-01T00:00:001992Estimation of completeness and adjustment of age-specific and age-standardized incidence rates.9376191Van den Berg CL, Cox GN, Stroh CA, Hilsenbeck SG, Weng CN, McDermott MJ, Pratt D, Osborne CK, Coronado-Heinsohn EB, Yee DEuropean journal of cancer (Oxford, England : 1990)Polyethylene glycol conjugated insulin-like growth factor binding protein-1 (IGFBP-1) inhibits growth of breast cancer in athymic mice. Eur J Cancer. 1997 Jun; 33(7):1108-13.Eur J Cancer1997-06-01T00:00:001997Polyethylene glycol conjugated insulin-like growth factor binding protein-1 (IGFBP-1) inhibits growth of breast cancer in athymic mice.9131271Gr?ndahl-Hansen J, Hilsenbeck SG, Christensen IJ, Clark GM, Osborne CK, Br?nner NBreast cancer research and treatmentPrognostic significance of PAI-1 and uPA in cytosolic extracts obtained from node-positive breast cancer patients. Breast Cancer Res Treat. 1997 Apr; 43(2):153-63.Breast Cancer Res Treat1997-04-01T00:00:001997Prognostic significance of PAI-1 and uPA in cytosolic extracts obtained from node-positive breast cancer patients.9426325Sharma S, Raymond E, Soda H, Sun D, Hilsenbeck SG, Sharma A, Izbicka E, Windle B, Von Hoff DDAnnals of oncology : official journal of the European Society for Medical OncologyPreclinical and clinical strategies for development of telomerase and telomere inhibitors. Ann Oncol. 1997 Nov; 8(11):1063-74.Ann Oncol1997-11-01T00:00:001997Preclinical and clinical strategies for development of telomerase and telomere inhibitors.8049503Shimada Y, Rothenberg M, Hilsenbeck SG, Burris HA, Degen D, Von Hoff DDAnti-cancer drugsActivity of CPT-11 (irinotecan hydrochloride), a topoisomerase I inhibitor, against human tumor colony-forming units. Anticancer Drugs. 1994 Apr; 5(2):202-6.Anticancer Drugs1994-04-01T00:00:001994Activity of CPT-11 (irinotecan hydrochloride), a topoisomerase I inhibitor, against human tumor colony-forming units.9455888Jenson HB, Grant GM, Ench Y, Heard P, Thomas CA, Hilsenbeck SG, Moyer MPClinical and diagnostic laboratory immunologyImmunofluorescence microscopy and flow cytometry characterization of chemical induction of latent Epstein-Barr virus. Clin Diagn Lab Immunol. 1998 Jan; 5(1):91-7.Clin Diagn Lab Immunol1998-01-01T00:00:001998Immunofluorescence microscopy and flow cytometry characterization of chemical induction of latent Epstein-Barr virus.9485488Hopp RM, Ransom N, Hilsenbeck SG, Papermaster DS, Windle JJMolecular visionApoptosis in the murine rd1 retinal degeneration is predominantly p53-independent. Mol Vis. 1998 Mar 02; 4:5.Mol Vis1998-03-02T00:00:001998Apoptosis in the murine rd1 retinal degeneration is predominantly p53-independent.9187170De Nino LA, Lawrence VA, Averyt EC, Hilsenbeck SG, Dhanda R, Page CPChestPreoperative spirometry and laparotomy: blowing away dollars. Chest. 1997 Jun; 111(6):1536-41.Chest1997-06-01T00:00:001997Preoperative spirometry and laparotomy: blowing away dollars.1359152Holzmayer TA, Hilsenbeck S, Von Hoff DD, Roninson IBJournal of the National Cancer InstituteClinical correlates of MDR1 (P-glycoprotein) gene expression in ovarian and small-cell lung carcinomas. J Natl Cancer Inst. 1992 Oct 07; 84(19):1486-91.J Natl Cancer Inst1992-10-07T00:00:001992Clinical correlates of MDR1 (P-glycoprotein) gene expression in ovarian and small-cell lung carcinomas.9815544Rocha RL, Hilsenbeck SG, Jackson JG, VanDenBerg CL, Weng Cn, Lee AV, Yee DClinical cancer research : an official journal of the American Association for Cancer ResearchInsulin-like growth factor binding protein-3 and insulin receptor substrate-1 in breast cancer: correlation with clinical parameters and disease-free survival. Clin Cancer Res. 1997 Jan; 3(1):103-9.Clin Cancer Res1997-01-01T00:00:001997Insulin-like growth factor binding protein-3 and insulin receptor substrate-1 in breast cancer: correlation with clinical parameters and disease-free survival.9816288Oesterreich S, Hilsenbeck SG, Ciocca DR, Allred DC, Clark GM, Chamness GC, Osborne CK, Fuqua SAClinical cancer research : an official journal of the American Association for Cancer ResearchThe small heat shock protein HSP27 is not an independent prognostic marker in axillary lymph node-negative breast cancer patients. Clin Cancer Res. 1996 Jul; 2(7):1199-206.Clin Cancer Res1996-07-01T00:00:001996The small heat shock protein HSP27 is not an independent prognostic marker in axillary lymph node-negative breast cancer patients.8328408Hilsenbeck SG, Raub WA, Sridhar KSAmerican journal of clinical oncologyPrognostic factors in lung cancer based on multivariate analysis. Am J Clin Oncol. 1993 Aug; 16(4):301-9.Am J Clin Oncol1993-08-01T00:00:001993Prognostic factors in lung cancer based on multivariate analysis.10066085Hilsenbeck SG, Ravdin PM, de Moor CA, Chamness GC, Osborne CK, Clark GMBreast cancer research and treatmentTime-dependence of hazard ratios for prognostic factors in primary breast cancer. Breast Cancer Res Treat. 1998; 52(1-3):227-37.Breast Cancer Res Treat1998-01-01T00:00:001998Time-dependence of hazard ratios for prognostic factors in primary breast cancer.10088614Hilsenbeck SG, Von Hoff DDJournal of the National Cancer InstituteMeasure once or twice -- does it really matter? J Natl Cancer Inst. 1999 Mar 17; 91(6):494-5.J Natl Cancer Inst1999-03-17T00:00:001999Measure once or twice -- does it really matter?1391974Ravdin PM, Clark GM, Hilsenbeck SG, Owens MA, Vendely P, Pandian MR, McGuire WLBreast cancer research and treatmentA demonstration that breast cancer recurrence can be predicted by neural network analysis. Breast Cancer Res Treat. 1992; 21(1):47-53.Breast Cancer Res Treat1992-01-01T00:00:001992A demonstration that breast cancer recurrence can be predicted by neural network analysis.1391986Hilsenbeck SG, Clark GM, McGuire WLBreast cancer research and treatmentWhy do so many prognostic factors fail to pan out? Breast Cancer Res Treat. 1992; 22(3):197-206.Breast Cancer Res Treat1992-01-01T00:00:001992Why do so many prognostic factors fail to pan out?1394041Sevin BU, Nadji M, Averette HE, Hilsenbeck S, Smith D, Lampe BCancerMicroinvasive carcinoma of the cervix. Cancer. 1992 Oct 15; 70(8):2121-8.Cancer1992-10-15T00:00:001992Microinvasive carcinoma of the cervix.1331485Burris HA, Hanauske AR, Johnson RK, Marshall MH, Kuhn JG, Hilsenbeck SG, Von Hoff DDJournal of the National Cancer InstituteActivity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units in vitro. J Natl Cancer Inst. 1992 Dec 02; 84(23):1816-20.J Natl Cancer Inst1992-12-02T00:00:001992Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units in vitro.10395871Leach CT, Koo FC, Hilsenbeck SG, Jenson HBThe Journal of infectious diseasesThe epidemiology of viral hepatitis in children in South Texas: increased prevalence of hepatitis A along the Texas-Mexico border. J Infect Dis. 1999 Aug; 180(2):509-13.J Infect Dis1999-08-01T00:00:001999The epidemiology of viral hepatitis in children in South Texas: increased prevalence of hepatitis A along the Texas-Mexico border.9501191Lavinsky RM, Jepsen K, Heinzel T, Torchia J, Mullen TM, Schiff R, Del-Rio AL, Ricote M, Ngo S, Gemsch J, Hilsenbeck SG, Osborne CK, Glass CK, Rosenfeld MG, Rose DWProceedings of the National Academy of Sciences of the United States of AmericaDiverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes. Proc Natl Acad Sci U S A. 1998 Mar 17; 95(6):2920-5.Proc Natl Acad Sci U S A1998-03-17T00:00:001998Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes.Authorship 28148210Authorship 2814836Authorship 2814848Authorship 2814852410451444O'Connell P, Fischbach K, Hilsenbeck S, Mohsin SK, Fuqua SA, Clark GM, Osborne CK, Allred DCJournal of the National Cancer InstituteLoss of heterozygosity at D14S62 and metastatic potential of breast cancer. J Natl Cancer Inst. 1999 Aug 18; 91(16):1391-7.J Natl Cancer Inst1999-08-18T00:00:001999Loss of heterozygosity at D14S62 and metastatic potential of breast cancer.26822237Parsons DW, Roy A, Yang Y, Wang T, Scollon S, Bergstrom K, Kerstein RA, Gutierrez S, Petersen AK, Bavle A, Lin FY, L?pez-Terrada DH, Monzon FA, Hicks MJ, Eldin KW, Quintanilla NM, Adesina AM, Mohila CA, Whitehead W, Jea A, Vasudevan SA, Nuchtern JG, Ramamurthy U, McGuire AL, Hilsenbeck SG, Reid JG, Muzny DM, Wheeler DA, Berg SL, Chintagumpala MM, Eng CM, Gibbs RA, Plon SEJAMA oncologyDiagnostic Yield of Clinical Tumor and Germline Whole-Exome Sequencing for Children With Solid Tumors. JAMA Oncol. 2016 May 01; 2(5):616-624.JAMA Oncol2016-05-01T00:00:002016Diagnostic Yield of Clinical Tumor and Germline Whole-Exome Sequencing for Children With Solid Tumors.26921331den Hollander P, Rawls K, Tsimelzon A, Shepherd J, Mazumdar A, Hill J, Fuqua SA, Chang JC, Osborne CK, Hilsenbeck SG, Mills GB, Brown PHCancer researchPhosphatase PTP4A3 Promotes Triple-Negative Breast Cancer Growth and Predicts Poor Patient Survival. Cancer Res. 2016 04 01; 76(7):1942-53.Cancer Res2016-02-26T00:00:002016Phosphatase PTP4A3 Promotes Triple-Negative Breast Cancer Growth and Predicts Poor Patient Survival.26894864Shepherd JH, Uray IP, Mazumdar A, Tsimelzon A, Savage M, Hilsenbeck SG, Brown PHOncotargetThe SOX11 transcription factor is a critical regulator of basal-like breast cancer growth, invasion, and basal-like gene expression. Oncotarget. 2016 Mar 15; 7(11):13106-21.Oncotarget2016-03-15T00:00:002016The SOX11 transcription factor is a critical regulator of basal-like breast cancer growth, invasion, and basal-like gene expression.26833126Nikolai BC, Lanz RB, York B, Dasgupta S, Mitsiades N, Creighton CJ, Tsimelzon A, Hilsenbeck SG, Lonard DM, Smith CL, O'Malley BWCancer researchHER2 Signaling Drives DNA Anabolism and Proliferation through SRC-3 Phosphorylation and E2F1-Regulated Genes. Cancer Res. 2016 Mar 15; 76(6):1463-75.Cancer Res2016-02-01T00:00:002016HER2 Signaling Drives DNA Anabolism and Proliferation through SRC-3 Phosphorylation and E2F1-Regulated Genes.9702938Lemieux P, Oesterreich S, Lawrence JA, Steeg PS, Hilsenbeck SG, Harvey JM, Fuqua SAInvasion & metastasisThe small heat shock protein hsp27 increases invasiveness but decreases motility of breast cancer cells. Invasion Metastasis. 1997; 17(3):113-23.Invasion Metastasis1997-01-01T00:00:001997The small heat shock protein hsp27 increases invasiveness but decreases motility of breast cancer cells.Authorship 2980557Authorship 30141289731725Allred DC, Hilsenbeck SGJournal of the National Cancer InstituteBiomarkers in benign breast disease: risk factors for breast cancer. J Natl Cancer Inst. 1998 Sep 02; 90(17):1247-8.J Natl Cancer Inst1998-09-02T00:00:001998Biomarkers in benign breast disease: risk factors for breast cancer.Authorship 30478712Authorship 30587438609661Rocha RL, Hilsenbeck SG, Jackson JG, Lee AV, Figueroa JA, Yee DJournal of the National Cancer InstituteCorrelation of insulin-like growth factor-binding protein-3 messenger RNA with protein expression in primary breast cancer tissues: detection of higher levels in tumors with poor prognostic features. J Natl Cancer Inst. 1996 May 01; 88(9):601-6.J Natl Cancer Inst1996-05-01T00:00:001996Correlation of insulin-like growth factor-binding protein-3 messenger RNA with protein expression in primary breast cancer tissues: detection of higher levels in tumors with poor prognostic features.26146825Shi A, Dong J, Hilsenbeck S, Bi L, Zhang H, Li YPloS oneThe Status of STAT3 and STAT5 in Human Breast Atypical Ductal Hyperplasia. PLoS One. 2015; 10(7):e0132214.PLoS One2015-07-06T00:00:002015The Status of STAT3 and STAT5 in Human Breast Atypical Ductal Hyperplasia.26166574Zheng ZY, Tian L, Bu W, Fan C, Gao X, Wang H, Liao YH, Li Y, Lewis MT, Edwards D, Zwaka TP, Hilsenbeck SG, Medina D, Perou CM, Creighton CJ, Zhang XH, Chang ECCell reportsWild-Type N-Ras, Overexpressed in Basal-like Breast Cancer, Promotes Tumor Formation by Inducing IL-8 Secretion via JAK2 Activation. Cell Rep. 2015 Jul 21; 12(3):511-24.Cell Rep2015-07-09T00:00:002015Wild-Type N-Ras, Overexpressed in Basal-like Breast Cancer, Promotes Tumor Formation by Inducing IL-8 Secretion via JAK2 Activation.26373672Villanueva H, Visbal AP, Obeid NF, Ta AQ, Faruki AA, Wu MF, Hilsenbeck SG, Shaw CA, Yu P, Plummer NW, Birnbaumer L, Lewis MTScience signalingAn essential role for Ga(i2) in Smoothened-stimulated epithelial cell proliferation in the mammary gland. Sci Signal. 2015 Sep 15; 8(394):ra92.Sci Signal2015-09-15T00:00:002015An essential role for Ga(i2) in Smoothened-stimulated epithelial cell proliferation in the mammary gland.26581390Holdman XB, Welte T, Rajapakshe K, Pond A, Coarfa C, Mo Q, Huang S, Hilsenbeck SG, Edwards DP, Zhang X, Rosen JMBreast cancer research : BCRUpregulation of EGFR signaling is correlated with tumor stroma remodeling and tumor recurrence in FGFR1-driven breast cancer. Breast Cancer Res. 2015 Nov 18; 17:141.Breast Cancer Res2015-11-18T00:00:002015Upregulation of EGFR signaling is correlated with tumor stroma remodeling and tumor recurrence in FGFR1-driven breast cancer.10999763Wu K, Kim HT, Rodriquez JL, Munoz-Medellin D, Mohsin SK, Hilsenbeck SG, Lamph WW, Gottardis MM, Shirley MA, Kuhn JG, Green JE, Brown PHClinical cancer research : an official journal of the American Association for Cancer Research9-cis-Retinoic acid suppresses mammary tumorigenesis in C3(1)-simian virus 40 T antigen-transgenic mice. Clin Cancer Res. 2000 Sep; 6(9):3696-704.Clin Cancer Res2000-09-01T00:00:0020009-cis-Retinoic acid suppresses mammary tumorigenesis in C3(1)-simian virus 40 T antigen-transgenic mice.9815968Murphy LC, Hilsenbeck SG, Dotzlaw H, Fuqua SAClinical cancer research : an official journal of the American Association for Cancer ResearchRelationship of clone 4 estrogen receptor variant messenger RNA expression to some known prognostic variables in human breast cancer. Clin Cancer Res. 1995 Feb; 1(2):155-9.Clin Cancer Res1995-02-01T00:00:001995Relationship of clone 4 estrogen receptor variant messenger RNA expression to some known prognostic variables in human breast cancer.8770719Lawrence VA, Hilsenbeck SG, Mulrow CD, Dhanda R, Sapp J, Page CPJournal of general internal medicineIncidence and hospital stay for cardiac and pulmonary complications after abdominal surgery. J Gen Intern Med. 1995 Dec; 10(12):671-8.J Gen Intern Med1995-12-01T00:00:001995Incidence and hospital stay for cardiac and pulmonary complications after abdominal surgery.8797421Lawrence VA, Dhanda R, Hilsenbeck SG, Page CPChestRisk of pulmonary complications after elective abdominal surgery. Chest. 1996 Sep; 110(3):744-50.Chest1996-09-01T00:00:001996Risk of pulmonary complications after elective abdominal surgery.11410514Chang J, Hilsenbeck SG, Sng JH, Wong J, Ragu GCClinical cancer research : an official journal of the American Association for Cancer ResearchPathological features and BRCA1 mutation screening in premenopausal breast cancer patients. Clin Cancer Res. 2001 Jun; 7(6):1739-42.Clin Cancer Res2001-06-01T00:00:002001Pathological features and BRCA1 mutation screening in premenopausal breast cancer patients.9001226Hundley JE, Koester SK, Troyer DA, Hilsenbeck SG, Subler MA, Windle JJMolecular and cellular biologyIncreased tumor proliferation and genomic instability without decreased apoptosis in MMTV-ras mice deficient in p53. Mol Cell Biol. 1997 Feb; 17(2):723-31.Mol Cell Biol1997-02-01T00:00:001997Increased tumor proliferation and genomic instability without decreased apoptosis in MMTV-ras mice deficient in p53.9010317Zhang QX, Hilsenbeck SG, Fuqua SA, Borg AThe Journal of steroid biochemistry and molecular biologyMultiple splicing variants of the estrogen receptor are present in individual human breast tumors. J Steroid Biochem Mol Biol. 1996 Nov; 59(3-4):251-60.J Steroid Biochem Mol Biol1996-11-01T00:00:001996Multiple splicing variants of the estrogen receptor are present in individual human breast tumors.1581829Sridhar KS, Hussein AM, Hilsenbeck S, Cairns VCancer investigationFive-drug antiemetic combination for cisplatin chemotherapy. Cancer Invest. 1992; 10(3):191-9.Cancer Invest1992-01-01T00:00:001992Five-drug antiemetic combination for cisplatin chemotherapy.10573111Hansen RK, Parra I, Lemieux P, Oesterreich S, Hilsenbeck SG, Fuqua SABreast cancer research and treatmentHsp27 overexpression inhibits doxorubicin-induced apoptosis in human breast cancer cells. Breast Cancer Res Treat. 1999 Jul; 56(2):187-96.Breast Cancer Res Treat1999-07-01T00:00:001999Hsp27 overexpression inhibits doxorubicin-induced apoptosis in human breast cancer cells.9044833Hundley JE, Koester SK, Troyer DA, Hilsenbeck SG, Barrington RE, Windle JJCancer researchDifferential regulation of cell cycle characteristics and apoptosis in MMTV-myc and MMTV-ras mouse mammary tumors. Cancer Res. 1997 Feb 15; 57(4):600-3.Cancer Res1997-02-15T00:00:001997Differential regulation of cell cycle characteristics and apoptosis in MMTV-myc and MMTV-ras mouse mammary tumors.12010861Wu K, Kim HT, Rodriquez JL, Hilsenbeck SG, Mohsin SK, Xu XC, Lamph WW, Kuhn JG, Green JE, Brown PHCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive OncologySuppression of mammary tumorigenesis in transgenic mice by the RXR-selective retinoid, LGD1069. Cancer Epidemiol Biomarkers Prev. 2002 May; 11(5):467-74.Cancer Epidemiol Biomarkers Prev2002-05-01T00:00:002002Suppression of mammary tumorigenesis in transgenic mice by the RXR-selective retinoid, LGD1069.1592380Hilsenbeck SG, Allred DCHuman pathologyImproved methods of estimating mitotic activity in solid tumors. Hum Pathol. 1992 Jun; 23(6):601-2.Hum Pathol1992-06-01T00:00:001992Improved methods of estimating mitotic activity in solid tumors.12083633Sivaraman L, Gay J, Hilsenbeck SG, Shine HD, Conneely OM, Medina D, O'Malley BWBreast cancer research and treatmentEffect of selective ablation of proliferating mammary epithelial cells on MNU induced rat mammary tumorigenesis. Breast Cancer Res Treat. 2002 May; 73(1):75-83.Breast Cancer Res Treat2002-05-01T00:00:002002Effect of selective ablation of proliferating mammary epithelial cells on MNU induced rat mammary tumorigenesis.Authorship 3153038Authorship 31530489215861Ravdin PM, de Moor CA, Hilsenbeck SG, Samoszuk MK, Vendely PM, Clark GMCancer lettersLack of prognostic value of cathepsin D levels for predicting short term outcomes of breast cancer patients. Cancer Lett. 1997 Jun 24; 116(2):177-83.Cancer Lett1997-06-24T00:00:001997Lack of prognostic value of cathepsin D levels for predicting short term outcomes of breast cancer patients.10827236Fernandes NF, Schwesinger WH, Hilsenbeck SG, Gross GW, Bay MK, Sirinek KR, Schenker SLiver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation SocietyLaparoscopic cholecystectomy and cirrhosis: a case-control study of outcomes. Liver Transpl. 2000 May; 6(3):340-4.Liver Transpl2000-05-01T00:00:002000Laparoscopic cholecystectomy and cirrhosis: a case-control study of outcomes.1623215Hanauske AR, Degen D, Marshall MH, Hilsenbeck SG, McPhillips JJ, Von Hoff DDAnti-cancer drugsPreclinical activity of ilmofosine against human tumor colony forming units in vitro. Anticancer Drugs. 1992 Feb; 3(1):43-6.Anticancer Drugs1992-02-01T00:00:001992Preclinical activity of ilmofosine against human tumor colony forming units in vitro.12438218Wu K, Zhang Y, Xu XC, Hill J, Celestino J, Kim HT, Mohsin SK, Hilsenbeck SG, Lamph WW, Bissonette R, Brown PHCancer researchThe retinoid X receptor-selective retinoid, LGD1069, prevents the development of estrogen receptor-negative mammary tumors in transgenic mice. Cancer Res. 2002 Nov 15; 62(22):6376-80.Cancer Res2002-11-15T00:00:002002The retinoid X receptor-selective retinoid, LGD1069, prevents the development of estrogen receptor-negative mammary tumors in transgenic mice.10906510Han E, Hilsenbeck SG, Richardson A, Nelson JFMechanisms of ageing and developmentcDNA expression arrays reveal incomplete reversal of age-related changes in gene expression by calorie restriction. Mech Ageing Dev. 2000 Jun 20; 115(3):157-74.Mech Ageing Dev2000-06-20T00:00:002000cDNA expression arrays reveal incomplete reversal of age-related changes in gene expression by calorie restriction.10945602Fuqua SA, Wiltschke C, Zhang QX, Borg A, Castles CG, Friedrichs WE, Hopp T, Hilsenbeck S, Mohsin S, O'Connell P, Allred DCCancer researchA hypersensitive estrogen receptor-alpha mutation in premalignant breast lesions. Cancer Res. 2000 Aug 01; 60(15):4026-9.Cancer Res2000-08-01T00:00:002000A hypersensitive estrogen receptor-alpha mutation in premalignant breast lesions.10959900Weitman S, Barrera H, Moore R, Gonzalez C, Marty J, Hilsenbeck S, MacDonald JR, Waters SJ, Von Hoff DJournal of pediatric hematology/oncologyMGI 114: augmentation of antitumor activity when combined with topotecan. J Pediatr Hematol Oncol. 2000 Jul-Aug; 22(4):306-14.J Pediatr Hematol Oncol2000-07-01T00:00:002000MGI 114: augmentation of antitumor activity when combined with topotecan.9407959Clark GM, Allred DC, Hilsenbeck SG, Chamness GC, Osborne CK, Jones D, Lee WHCancer researchMitosin (a new proliferation marker) correlates with clinical outcome in node-negative breast cancer. Cancer Res. 1997 Dec 15; 57(24):5505-8.Cancer Res1997-12-15T00:00:001997Mitosin (a new proliferation marker) correlates with clinical outcome in node-negative breast cancer.11041564Przepiorka D, Blamble D, Hilsenbeck S, Danielson M, Krance R, Chan KWBone marrow transplantationTacrolimus clearance is age-dependent within the pediatric population. Bone Marrow Transplant. 2000 Sep; 26(6):601-5.Bone Marrow Transplant2000-09-01T00:00:002000Tacrolimus clearance is age-dependent within the pediatric population.9547680Sharma JJ, Razvillas B, Stephens CD, Hilsenbeck SG, Sharma A, Rothenberg MLInvestigational new drugsPhase II study of flutamide as second line chemotherapy in patients with advanced pancreatic cancer. Invest New Drugs. 1997; 15(4):361-4.Invest New Drugs1997-01-01T00:00:001997Phase II study of flutamide as second line chemotherapy in patients with advanced pancreatic cancer.1514535Sridhar KS, Raub WA, Duncan RC, Hilsenbeck SAmerican journal of clinical oncologyThe increasing recognition of adenosquamous lung carcinoma (1977-1986). Am J Clin Oncol. 1992 Aug; 15(4):356-62.Am J Clin Oncol1992-08-01T00:00:001992The increasing recognition of adenosquamous lung carcinoma (1977-1986).9586875Diab SG, Hilsenbeck SG, de Moor C, Clark GM, Osborne CK, Ravdin PM, Elledge RMJournal of clinical oncology : official journal of the American Society of Clinical OncologyRadiation therapy and survival in breast cancer patients with 10 or more positive axillary lymph nodes treated with mastectomy. J Clin Oncol. 1998 May; 16(5):1655-60.J Clin Oncol1998-05-01T00:00:001998Radiation therapy and survival in breast cancer patients with 10 or more positive axillary lymph nodes treated with mastectomy.27003444Marcelo KL, Ribar T, Means CR, Tsimelzon A, Stevens RD, Ilkayeva O, Bain JR, Hilsenbeck SG, Newgard CB, Means AR, York BMolecular endocrinology (Baltimore, Md.)Research Resource: Roles for Calcium/Calmodulin-Dependent Protein Kinase Kinase 2 (CaMKK2) in Systems Metabolism. Mol Endocrinol. 2016 May; 30(5):557-72.Mol Endocrinol2016-03-22T00:00:002016Research Resource: Roles for Calcium/Calmodulin-Dependent Protein Kinase Kinase 2 (CaMKK2) in Systems Metabolism.26965145Malorni L, Giuliano M, Migliaccio I, Wang T, Creighton CJ, Lupien M, Fu X, Hilsenbeck SG, Healy N, De Angelis C, Mazumdar A, Trivedi MV, Massarweh S, Gutierrez C, De Placido S, Jeselsohn R, Brown M, Brown PH, Osborne CK, Schiff RMolecular cancer research : MCRBlockade of AP-1 Potentiates Endocrine Therapy and Overcomes Resistance. Mol Cancer Res. 2016 05; 14(5):470-81.Mol Cancer Res2016-03-10T00:00:002016Blockade of AP-1 Potentiates Endocrine Therapy and Overcomes Resistance.1515420Hanauske AR, Degen D, Marshall MH, Hilsenbeck SG, Banks P, Stuckey J, Leahy M, Von Hoff DDJournal of immunotherapy : official journal of the Society for Biological TherapyEffects of recombinant human interleukin-1 alpha on clonogenic growth of primary human tumors in vitro. J Immunother (1991). 1992 Apr; 11(3):155-8.J Immunother (1991)1992-04-01T00:00:001992Effects of recombinant human interleukin-1 alpha on clonogenic growth of primary human tumors in vitro.1356030Hanauske AR, Degen D, Hilsenbeck SG, Bissery MC, Von Hoff DDAnti-cancer drugsEffects of Taxotere and taxol on in vitro colony formation of freshly explanted human tumor cells. Anticancer Drugs. 1992 Apr; 3(2):121-4.Anticancer Drugs1992-04-01T00:00:001992Effects of Taxotere and taxol on in vitro colony formation of freshly explanted human tumor cells.1525392Hanauske AR, Degen D, Marshall MH, Hilsenbeck SG, Grindey GB, Von Hoff DDAnti-cancer drugsActivity of 2',2'-difluorodeoxycytidine (Gemcitabine) against human tumor colony forming units. Anticancer Drugs. 1992 Apr; 3(2):143-6.Anticancer Drugs1992-04-01T00:00:001992Activity of 2',2'-difluorodeoxycytidine (Gemcitabine) against human tumor colony forming units.10070945Hilsenbeck SG, Friedrichs WE, Schiff R, O'Connell P, Hansen RK, Osborne CK, Fuqua SAJournal of the National Cancer InstituteStatistical analysis of array expression data as applied to the problem of tamoxifen resistance. J Natl Cancer Inst. 1999 Mar 03; 91(5):453-9.J Natl Cancer Inst1999-03-03T00:00:001999Statistical analysis of array expression data as applied to the problem of tamoxifen resistance.10070962Britten CD, Hilsenbeck SG, Eckhardt SG, Marty J, Mangold G, MacDonald JR, Rowinsky EK, Von Hoff DD, Weitman SCancer researchEnhanced antitumor activity of 6-hydroxymethylacylfulvene in combination with irinotecan and 5-fluorouracil in the HT29 human colon tumor xenograft model. Cancer Res. 1999 Mar 01; 59(5):1049-53.Cancer Res1999-03-01T00:00:001999Enhanced antitumor activity of 6-hydroxymethylacylfulvene in combination with irinotecan and 5-fluorouracil in the HT29 human colon tumor xenograft model.10412943Britten CD, Izbicka E, Hilsenbeck S, Lawrence R, Davidson K, Cerna C, Gomez L, Rowinsky EK, Weitman S, Von Hoff DDCancer chemotherapy and pharmacologyActivity of the multitargeted antifolate LY231514 in the human tumor cloning assay. Cancer Chemother Pharmacol. 1999; 44(2):105-10.Cancer Chemother Pharmacol1999-01-01T00:00:001999Activity of the multitargeted antifolate LY231514 in the human tumor cloning assay.10528033Hilsenbeck SGJournal of the National Cancer InstituteRESPONSE: re: measure once or twice-does It really matter? J Natl Cancer Inst. 1999 Oct 20; 91(20):1780A-1781.J Natl Cancer Inst1999-10-20T00:00:001999RESPONSE: re: measure once or twice-does It really matter?14715110Van Pelt AE, Mohsin S, Elledge RM, Hilsenbeck SG, Gutierrez MC, Lucci A, Kalidas M, Granchi T, Scott BG, Allred DC, Chang JCClinical breast cancerNeoadjuvant trastuzumab and docetaxel in breast cancer: preliminary results. Clin Breast Cancer. 2003 Dec; 4(5):348-53.Clin Breast Cancer2003-12-01T00:00:002003Neoadjuvant trastuzumab and docetaxel in breast cancer: preliminary results.11795441Medina D, Sivaraman L, Hilsenbeck SG, Conneely O, Ginger M, Rosen J, Omalle BWAnnals of the New York Academy of SciencesMechanisms of hormonal prevention of breast cancer. Ann N Y Acad Sci. 2001 Dec; 952:23-35.Ann N Y Acad Sci2001-12-01T00:00:002001Mechanisms of hormonal prevention of breast cancer.1738187McGuire WL, Hilsenbeck S, Clark GMJournal of the National Cancer InstituteOptimal mastectomy timing. J Natl Cancer Inst. 1992 Mar 04; 84(5):346-8.J Natl Cancer Inst1992-03-04T00:00:001992Optimal mastectomy timing.10784631Zellars RC, Hilsenbeck SG, Clark GM, Allred DC, Herman TS, Chamness GC, Elledge RMJournal of clinical oncology : official journal of the American Society of Clinical OncologyPrognostic value of p53 for local failure in mastectomy-treated breast cancer patients. J Clin Oncol. 2000 May; 18(9):1906-13.J Clin Oncol2000-05-01T00:00:002000Prognostic value of p53 for local failure in mastectomy-treated breast cancer patients.1592280Wolfson AH, Sightler SE, Markoe AM, Schwade JG, Averette HE, Ganjei P, Hilsenbeck SGGynecologic oncologyThe prognostic significance of surgical staging for carcinoma of the endometrium. Gynecol Oncol. 1992 May; 45(2):142-6.Gynecol Oncol1992-05-01T00:00:001992The prognostic significance of surgical staging for carcinoma of the endometrium.74Professor42Director47Distinguished Service Professor11094320Hammond LA, Hilsenbeck SG, Eckhardt SG, Marty J, Mangold G, MacDonald JR, Rowinsky EK, Von Hoff DD, Weitman SEuropean journal of cancer (Oxford, England : 1990)Enhanced antitumour activity of 6-hydroxymethylacylfulvene in combination with topotecan or paclitaxel in the MV522 lung carcinoma xenograft model. Eur J Cancer. 2000 Dec; 36(18):2430-6.Eur J Cancer2000-12-01T00:00:002000Enhanced antitumour activity of 6-hydroxymethylacylfulvene in combination with topotecan or paclitaxel in the MV522 lung carcinoma xenograft model.11106684Schiff R, Reddy P, Ahotupa M, Coronado-Heinsohn E, Grim M, Hilsenbeck SG, Lawrence R, Deneke S, Herrera R, Chamness GC, Fuqua SA, Brown PH, Osborne CKJournal of the National Cancer InstituteOxidative stress and AP-1 activity in tamoxifen-resistant breast tumors in vivo. J Natl Cancer Inst. 2000 Dec 06; 92(23):1926-34.J Natl Cancer Inst2000-12-06T00:00:002000Oxidative stress and AP-1 activity in tamoxifen-resistant breast tumors in vivo.15687551Osborne CK, Elledge RM, Brown PH, Hilsenbeck SGBreast diseaseBRCA1 in clinical breast cancer. Breast Dis. 1998 Apr; 10(1-2):77-88.Breast Dis1998-04-01T00:00:001998BRCA1 in clinical breast cancer.11263990Hansen RK, Parra I, Hilsenbeck SG, Himelstein B, Fuqua SABiochemical and biophysical research communicationsHsp27-induced MMP-9 expression is influenced by the Src tyrosine protein kinase yes. Biochem Biophys Res Commun. 2001 Mar 23; 282(1):186-93.Biochem Biophys Res Commun2001-03-23T00:00:002001Hsp27-induced MMP-9 expression is influenced by the Src tyrosine protein kinase yes.11289680Leach CT, Koo FC, Kuhls TL, Hilsenbeck SG, Jenson HBThe American journal of tropical medicine and hygienePrevalence of Cryptosporidium parvum infection in children along the Texas-Mexico border and associated risk factors. Am J Trop Med Hyg. 2000 May; 62(5):656-61.Am J Trop Med Hyg2000-05-01T00:00:002000Prevalence of Cryptosporidium parvum infection in children along the Texas-Mexico border and associated risk factors.Breast Surgical Oncology15845616Jeong JW, Lee KY, Kwak I, White LD, Hilsenbeck SG, Lydon JP, DeMayo FJEndocrinologyIdentification of murine uterine genes regulated in a ligand-dependent manner by the progesterone receptor. Endocrinology. 2005 Aug; 146(8):3490-505.Endocrinology2005-04-21T00:00:002005Identification of murine uterine genes regulated in a ligand-dependent manner by the progesterone receptor.11420689Ludes-Meyers JH, Liu Y, Mu?oz-Medellin D, Hilsenbeck SG, Brown PHOncogeneAP-1 blockade inhibits the growth of normal and malignant breast cells. Oncogene. 2001 May 17; 20(22):2771-80.Oncogene2001-05-17T00:00:002001AP-1 blockade inhibits the growth of normal and malignant breast cells.15987438Chang JC, Hilsenbeck SG, Fuqua SABreast cancer research : BCRThe promise of microarrays in the management and treatment of breast cancer. Breast Cancer Res. 2005; 7(3):100-4.Breast Cancer Res2005-04-01T00:00:002005The promise of microarrays in the management and treatment of breast cancer.12704148Bourgogne A, Drysdale M, Hilsenbeck SG, Peterson SN, Koehler TMInfection and immunityGlobal effects of virulence gene regulators in a Bacillus anthracis strain with both virulence plasmids. Infect Immun. 2003 May; 71(5):2736-43.Infect Immun2003-05-01T00:00:002003Global effects of virulence gene regulators in a Bacillus anthracis strain with both virulence plasmids.16244788Martin MD, Hilsenbeck SG, Mohsin SK, Hopp TA, Clark GM, Osborne CK, Allred DC, O'Connell PBreast cancer research and treatmentBreast tumors that overexpress nuclear metastasis-associated 1 (MTA1) protein have high recurrence risks but enhanced responses to systemic therapies. Breast Cancer Res Treat. 2006 Jan; 95(1):7-12.Breast Cancer Res Treat2005-10-22T00:00:002005Breast tumors that overexpress nuclear metastasis-associated 1 (MTA1) protein have high recurrence risks but enhanced responses to systemic therapies.12039933Berry DA, Iversen ES, Gudbjartsson DF, Hiller EH, Garber JE, Peshkin BN, Lerman C, Watson P, Lynch HT, Hilsenbeck SG, Rubinstein WS, Hughes KS, Parmigiani GJournal of clinical oncology : official journal of the American Society of Clinical OncologyBRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. J Clin Oncol. 2002 Jun 01; 20(11):2701-12.J Clin Oncol2002-06-01T00:00:002002BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes.16467115Come SE, Buzdar AU, Ingle JN, Arteaga CL, Brown M, Dowsett M, Hilsenbeck SG, Kumar R, Johnston SR, Lee AV, Paik S, Pritchard KI, Winer EP, Hart CClinical cancer research : an official journal of the American Association for Cancer ResearchProceedings of the Fifth International Conference on Recent Advances and Future Directions in Endocrine Therapy for Breast Cancer: conference summary statement. Clin Cancer Res. 2006 Feb 01; 12(3 Pt 2):997s-1000s.Clin Cancer Res2006-02-01T00:00:002006Proceedings of the Fifth International Conference on Recent Advances and Future Directions in Endocrine Therapy for Breast Cancer: conference summary statement.16467118Kim HJ, Cui X, Hilsenbeck SG, Lee AVClinical cancer research : an official journal of the American Association for Cancer ResearchProgesterone receptor loss correlates with human epidermal growth factor receptor 2 overexpression in estrogen receptor-positive breast cancer. Clin Cancer Res. 2006 Feb 01; 12(3 Pt 2):1013s-1018s.Clin Cancer Res2006-02-01T00:00:002006Progesterone receptor loss correlates with human epidermal growth factor receptor 2 overexpression in estrogen receptor-positive breast cancer.Authorship 323132427052522Raj SD, Sedgwick EL, Severs FJ, Hilsenbeck SG, Wang T, Sepulveda KAAcademic radiologyStereotactic Biopsy of Segmental Breast Calcifications: Is Sampling of Anterior and Posterior Components Necessary? Acad Radiol. 2016 06; 23(6):682-6.Acad Radiol2016-04-01T00:00:002016Stereotactic Biopsy of Segmental Breast Calcifications: Is Sampling of Anterior and Posterior Components Necessary?16585749Bourgogne A, Hilsenbeck SG, Dunny GM, Murray BEJournal of bacteriologyComparison of OG1RF and an isogenic fsrB deletion mutant by transcriptional analysis: the Fsr system of Enterococcus faecalis is more than the activator of gelatinase and serine protease. J Bacteriol. 2006 Apr; 188(8):2875-84.J Bacteriol2006-04-01T00:00:002006Comparison of OG1RF and an isogenic fsrB deletion mutant by transcriptional analysis: the Fsr system of Enterococcus faecalis is more than the activator of gelatinase and serine protease.1606535Vogel CL, Azevedo S, Hilsenbeck S, East DR, Ayub JCancerSurvival after first recurrence of breast cancer. The Miami experience. Cancer. 1992 Jul 01; 70(1):129-35.Cancer1992-07-01T00:00:001992Survival after first recurrence of breast cancer. The Miami experience.16678816Shen Q, Zhang Y, Uray IP, Hill JL, Kim HT, Lu C, Young MR, Gunther EJ, Hilsenbeck SG, Chodosh LA, Colburn NH, Brown PHDevelopmental biologyThe AP-1 transcription factor regulates postnatal mammary gland development. Dev Biol. 2006 Jul 15; 295(2):589-603.Dev Biol2006-04-04T00:00:002006The AP-1 transcription factor regulates postnatal mammary gland development.One Baylor PlazaHouston, 77030TX12400010Liu Y, Ludes-Meyers J, Zhang Y, Munoz-Medellin D, Kim HT, Lu C, Ge G, Schiff R, Hilsenbeck SG, Osborne CK, Brown PHOncogeneInhibition of AP-1 transcription factor causes blockade of multiple signal transduction pathways and inhibits breast cancer growth. Oncogene. 2002 Oct 31; 21(50):7680-9.Oncogene2002-10-31T00:00:002002Inhibition of AP-1 transcription factor causes blockade of multiple signal transduction pathways and inhibits breast cancer growth.Authorship 3249521027393618Mazumdar A, Poage GM, Shepherd J, Tsimelzon A, Hartman ZC, Den Hollander P, Hill J, Zhang Y, Chang J, Hilsenbeck SG, Fuqua S, Kent Osborne C, Mills GB, Brown PHBreast cancer research and treatmentAnalysis of phosphatases in ER-negative breast cancers identifies DUSP4 as a critical regulator of growth and invasion. Breast Cancer Res Treat. 2016 08; 158(3):441-54.Breast Cancer Res Treat2016-07-08T00:00:002016Analysis of phosphatases in ER-negative breast cancers identifies DUSP4 as a critical regulator of growth and invasion.17008703Ma XJ, Hilsenbeck SG, Wang W, Ding L, Sgroi DC, Bender RA, Osborne CK, Allred DC, Erlander MGJournal of clinical oncology : official journal of the American Society of Clinical OncologyThe HOXB13:IL17BR expression index is a prognostic factor in early-stage breast cancer. J Clin Oncol. 2006 Oct 01; 24(28):4611-9.J Clin Oncol2006-10-01T00:00:002006The HOXB13:IL17BR expression index is a prognostic factor in early-stage breast cancer.Authorship 326266327407096Yuan Y, Hess KR, Hilsenbeck SG, Gilbert MRClinical cancer research : an official journal of the American Association for Cancer ResearchBayesian Optimal Interval Design: A Simple and Well-Performing Design for Phase I Oncology Trials. Clin Cancer Res. 2016 Sep 01; 22(17):4291-301.Clin Cancer Res2016-07-12T00:00:002016Bayesian Optimal Interval Design: A Simple and Well-Performing Design for Phase I Oncology Trials.14702298Drysdale M, Bourgogne A, Hilsenbeck SG, Koehler TMJournal of bacteriologyatxA controls Bacillus anthracis capsule synthesis via acpA and a newly discovered regulator, acpB. J Bacteriol. 2004 Jan; 186(2):307-15.J Bacteriol2004-01-01T00:00:002004atxA controls Bacillus anthracis capsule synthesis via acpA and a newly discovered regulator, acpB.12531793Liu Q, Hilsenbeck S, Gazitt YBloodArsenic trioxide-induced apoptosis in myeloma cells: p53-dependent G1 or G2/M cell cycle arrest, activation of caspase-8 or caspase-9, and synergy with APO2/TRAIL. Blood. 2003 May 15; 101(10):4078-87.Blood2003-01-16T00:00:002003Arsenic trioxide-induced apoptosis in myeloma cells: p53-dependent G1 or G2/M cell cycle arrest, activation of caspase-8 or caspase-9, and synergy with APO2/TRAIL.12618500Osborne CK, Bardou V, Hopp TA, Chamness GC, Hilsenbeck SG, Fuqua SA, Wong J, Allred DC, Clark GM, Schiff RJournal of the National Cancer InstituteRole of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst. 2003 Mar 05; 95(5):353-61.J Natl Cancer Inst2003-03-05T00:00:002003Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer.17468949Chang JC, Makris A, Gutierrez MC, Hilsenbeck SG, Hackett JR, Jeong J, Liu ML, Baker J, Clark-Langone K, Baehner FL, Sexton K, Mohsin S, Gray T, Alvarez L, Chamness GC, Osborne CK, Shak SBreast cancer research and treatmentGene expression patterns in formalin-fixed, paraffin-embedded core biopsies predict docetaxel chemosensitivity in breast cancer patients. Breast Cancer Res Treat. 2008 Mar; 108(2):233-40.Breast Cancer Res Treat2007-04-28T00:00:002007Gene expression patterns in formalin-fixed, paraffin-embedded core biopsies predict docetaxel chemosensitivity in breast cancer patients.15071073Han ES, Wu Y, McCarter R, Nelson JF, Richardson A, Hilsenbeck SGThe journals of gerontology. Series A, Biological sciences and medical sciencesReproducibility, sources of variability, pooling, and sample size: important considerations for the design of high-density oligonucleotide array experiments. J Gerontol A Biol Sci Med Sci. 2004 Apr; 59(4):306-15.J Gerontol A Biol Sci Med Sci2004-04-01T00:00:002004Reproducibility, sources of variability, pooling, and sample size: important considerations for the design of high-density oligonucleotide array experiments.15102680Hopp TA, Weiss HL, Hilsenbeck SG, Cui Y, Allred DC, Horwitz KB, Fuqua SAClinical cancer research : an official journal of the American Association for Cancer ResearchBreast cancer patients with progesterone receptor PR-A-rich tumors have poorer disease-free survival rates. Clin Cancer Res. 2004 Apr 15; 10(8):2751-60.Clin Cancer Res2004-04-15T00:00:002004Breast cancer patients with progesterone receptor PR-A-rich tumors have poorer disease-free survival rates.12907009Chang JC, Wooten EC, Tsimelzon A, Hilsenbeck SG, Gutierrez MC, Elledge R, Mohsin S, Osborne CK, Chamness GC, Allred DC, O'Connell PLancet (London, England)Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet. 2003 Aug 02; 362(9381):362-9.Lancet2003-08-02T00:00:002003Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer.18559513Zhang M, Behbod F, Atkinson RL, Landis MD, Kittrell F, Edwards D, Medina D, Tsimelzon A, Hilsenbeck S, Green JE, Michalowska AM, Rosen JMCancer researchIdentification of tumor-initiating cells in a p53-null mouse model of breast cancer. Cancer Res. 2008 Jun 15; 68(12):4674-82.Cancer Res2008-06-15T00:00:002008Identification of tumor-initiating cells in a p53-null mouse model of breast cancer.18757322Creighton CJ, Casa A, Lazard Z, Huang S, Tsimelzon A, Hilsenbeck SG, Osborne CK, Lee AVJournal of clinical oncology : official journal of the American Society of Clinical OncologyInsulin-like growth factor-I activates gene transcription programs strongly associated with poor breast cancer prognosis. J Clin Oncol. 2008 Sep 01; 26(25):4078-85.J Clin Oncol2008-09-01T00:00:002008Insulin-like growth factor-I activates gene transcription programs strongly associated with poor breast cancer prognosis.19088937Fisher WE, Hodges SE, Yagnik V, Mor?n FE, Wu MF, Hilsenbeck SG, Raijman IL, Brunicardi FCHPB : the official journal of the International Hepato Pancreato Biliary AssociationAccuracy of CT in predicting malignant potential of cystic pancreatic neoplasms. HPB (Oxford). 2008; 10(6):483-90.HPB (Oxford)2008-01-01T00:00:002008Accuracy of CT in predicting malignant potential of cystic pancreatic neoplasms.19138935Shen Q, Uray IP, Li Y, Zhang Y, Hill J, Xu XC, Young MR, Gunther EJ, Hilsenbeck SG, Colburn NH, Chodosh LA, Brown PHCancer prevention research (Philadelphia, Pa.)Targeting the activator protein 1 transcription factor for the prevention of estrogen receptor-negative mammary tumors. Cancer Prev Res (Phila). 2008 Jun; 1(1):45-55.Cancer Prev Res (Phila)2008-03-31T00:00:002008Targeting the activator protein 1 transcription factor for the prevention of estrogen receptor-negative mammary tumors.15714204Chang JC, Hilsenbeck SG, Fuqua SABritish journal of cancerGenomic approaches in the management and treatment of breast cancer. Br J Cancer. 2005 Feb 28; 92(4):618-24.Br J Cancer2005-02-28T00:00:002005Genomic approaches in the management and treatment of breast cancer.19391063El-Serag HB, Nurgalieva ZZ, Mistretta TA, Finegold MJ, Souza R, Hilsenbeck S, Shaw C, Darlington GScandinavian journal of gastroenterologyGene expression in Barrett's esophagus: laser capture versus whole tissue. Scand J Gastroenterol. 2009; 44(7):787-95.Scand J Gastroenterol2009-01-01T00:00:002009Gene expression in Barrett's esophagus: laser capture versus whole tissue.15795341Chen DT, Rosenstein DL, Muthappan P, Hilsenbeck SG, Miller FG, Emanuel EJ, Wendler DArchives of internal medicineResearch with stored biological samples: what do research participants want? Arch Intern Med. 2005 Mar 28; 165(6):652-5.Arch Intern Med2005-03-28T00:00:002005Research with stored biological samples: what do research participants want?19637041Chang JC, Hilsenbeck SG, Fuqua SACancer investigationPharmacogenetics of breast cancer: toward the individualization of therapy. Cancer Invest. 2009 Aug; 27(7):699-703.Cancer Invest2009-08-01T00:00:002009Pharmacogenetics of breast cancer: toward the individualization of therapy.19703301Heckman-Stoddard BM, Vargo-Gogola T, McHenry PR, Jiang V, Herrick MP, Hilsenbeck SG, Settleman J, Rosen JMBreast cancer research : BCRHaploinsufficiency for p190B RhoGAP inhibits MMTV-Neu tumor progression. Breast Cancer Res. 2009; 11(4):R61.Breast Cancer Res2009-08-24T00:00:002009Haploinsufficiency for p190B RhoGAP inhibits MMTV-Neu tumor progression.19924529Migliaccio I, Wu MF, Gutierrez C, Malorni L, Mohsin SK, Allred DC, Hilsenbeck SG, Osborne CK, Weiss H, Lee AVBreast cancer research and treatmentNuclear IRS-1 predicts tamoxifen response in patients with early breast cancer. Breast Cancer Res Treat. 2010 Oct; 123(3):651-60.Breast Cancer Res Treat2009-11-19T00:00:002009Nuclear IRS-1 predicts tamoxifen response in patients with early breast cancer.15150107Lin SC, Lee KF, Nikitin AY, Hilsenbeck SG, Cardiff RD, Li A, Kang KW, Frank SA, Lee WH, Lee EYCancer researchSomatic mutation of p53 leads to estrogen receptor alpha-positive and -negative mouse mammary tumors with high frequency of metastasis. Cancer Res. 2004 May 15; 64(10):3525-32.Cancer Res2004-05-15T00:00:002004Somatic mutation of p53 leads to estrogen receptor alpha-positive and -negative mouse mammary tumors with high frequency of metastasis.16261403Tham YL, Gomez LF, Mohsin S, Gutierrez MC, Weiss H, Hilsenbeck SG, Elledge RM, Chamness GC, Osborne CK, Allred DC, Chang JCBreast cancer research and treatmentClinical response to neoadjuvant docetaxel predicts improved outcome in patients with large locally advanced breast cancers. Breast Cancer Res Treat. 2005 Dec; 94(3):279-84.Breast Cancer Res Treat2005-12-01T00:00:002005Clinical response to neoadjuvant docetaxel predicts improved outcome in patients with large locally advanced breast cancers.15514030DeNardo DG, Kim HT, Hilsenbeck S, Cuba V, Tsimelzon A, Brown PHMolecular endocrinology (Baltimore, Md.)Global gene expression analysis of estrogen receptor transcription factor cross talk in breast cancer: identification of estrogen-induced/activator protein-1-dependent genes. Mol Endocrinol. 2005 Feb; 19(2):362-78.Mol Endocrinol2004-10-28T00:00:002004Global gene expression analysis of estrogen receptor transcription factor cross talk in breast cancer: identification of estrogen-induced/activator protein-1-dependent genes.21224735Plon SE, Cooper HP, Parks B, Dhar SU, Kelly PA, Weinberg AD, Staggs S, Wang T, Hilsenbeck SGenetics in medicine : official journal of the American College of Medical GeneticsGenetic testing and cancer risk management recommendations by physicians for at-risk relatives. Genet Med. 2011 Feb; 13(2):148-54.Genet Med2011-02-01T00:00:002011Genetic testing and cancer risk management recommendations by physicians for at-risk relatives.15572750Kalidas M, Hilsenbeck S, Brown PJournal of the National Cancer InstituteDefining the role of raloxifene for the prevention of breast cancer. J Natl Cancer Inst. 2004 Dec 01; 96(23):1731-3.J Natl Cancer Inst2004-12-01T00:00:002004Defining the role of raloxifene for the prevention of breast cancer.21376233Sun T, Aceto N, Meerbrey KL, Kessler JD, Zhou C, Migliaccio I, Nguyen DX, Pavlova NN, Botero M, Huang J, Bernardi RJ, Schmitt E, Hu G, Li MZ, Dephoure N, Gygi SP, Rao M, Creighton CJ, Hilsenbeck SG, Shaw CA, Muzny D, Gibbs RA, Wheeler DA, Osborne CK, Schiff R, Bentires-Alj M, Elledge SJ, Westbrook TFCellActivation of multiple proto-oncogenic tyrosine kinases in breast cancer via loss of the PTPN12 phosphatase. Cell. 2011 Mar 04; 144(5):703-18.Cell2011-03-04T00:00:002011Activation of multiple proto-oncogenic tyrosine kinases in breast cancer via loss of the PTPN12 phosphatase.16417654Lee S, Mohsin SK, Mao S, Hilsenbeck SG, Medina D, Allred DCBreast cancer research : BCRHormones, receptors, and growth in hyperplastic enlarged lobular units: early potential precursors of breast cancer. Breast Cancer Res. 2006; 8(1):R6.Breast Cancer Res2005-12-16T00:00:002005Hormones, receptors, and growth in hyperplastic enlarged lobular units: early potential precursors of breast cancer.21447808Barone I, Brusco L, Gu G, Selever J, Beyer A, Covington KR, Tsimelzon A, Wang T, Hilsenbeck SG, Chamness GC, And? S, Fuqua SAJournal of the National Cancer InstituteLoss of Rho GDIa and resistance to tamoxifen via effects on estrogen receptor a. J Natl Cancer Inst. 2011 Apr 06; 103(7):538-52.J Natl Cancer Inst2011-03-29T00:00:002011Loss of Rho GDIa and resistance to tamoxifen via effects on estrogen receptor a.Authorship 3281651627671678Marusyk A, Tabassum DP, Janiszewska M, Place AE, Trinh A, Rozhok AI, Pyne S, Guerriero JL, Shu S, Ekram M, Ishkin A, Cahill DP, Nikolsky Y, Chan TA, Rimawi MF, Hilsenbeck S, Schiff R, Osborne KC, Letai A, Polyak KCancer researchSpatial Proximity to Fibroblasts Impacts Molecular Features and Therapeutic Sensitivity of Breast Cancer Cells Influencing Clinical Outcomes. Cancer Res. 2016 11 15; 76(22):6495-6506.Cancer Res2016-09-26T00:00:002016Spatial Proximity to Fibroblasts Impacts Molecular Features and Therapeutic Sensitivity of Breast Cancer Cells Influencing Clinical Outcomes.21541704Casa AJ, Potter AS, Malik S, Lazard Z, Kuiatse I, Kim HT, Tsimelzon A, Creighton CJ, Hilsenbeck SG, Brown PH, Oesterreich S, Lee AVBreast cancer research and treatmentEstrogen and insulin-like growth factor-I (IGF-I) independently down-regulate critical repressors of breast cancer growth. Breast Cancer Res Treat. 2012 Feb; 132(1):61-73.Breast Cancer Res Treat2011-05-04T00:00:002011Estrogen and insulin-like growth factor-I (IGF-I) independently down-regulate critical repressors of breast cancer growth.21590258Gazitt Y, Hilsenbeck SOncology reportsPitfalls in the RNA-based PCR amplification of the CDRIII sequence for quantitation of minimal residual disease in multiple myeloma (Commentary). Oncol Rep. 1997 Nov-Dec; 4(6):1387-90.Oncol Rep1997-11-01T00:00:001997Pitfalls in the RNA-based PCR amplification of the CDRIII sequence for quantitation of minimal residual disease in multiple myeloma (Commentary).15687696Fuqua SA, Chang JC, Hilsenbeck SGBreast diseaseGenomic approaches to understanding and treating breast cancer. Breast Dis. 2004; 19:35-46.Breast Dis2004-01-01T00:00:002004Genomic approaches to understanding and treating breast cancer.15718313Chang JC, Wooten EC, Tsimelzon A, Hilsenbeck SG, Gutierrez MC, Tham YL, Kalidas M, Elledge R, Mohsin S, Osborne CK, Chamness GC, Allred DC, Lewis MT, Wong H, O'Connell PJournal of clinical oncology : official journal of the American Society of Clinical OncologyPatterns of resistance and incomplete response to docetaxel by gene expression profiling in breast cancer patients. J Clin Oncol. 2005 Feb 20; 23(6):1169-77.J Clin Oncol2005-02-20T00:00:002005Patterns of resistance and incomplete response to docetaxel by gene expression profiling in breast cancer patients.21785360McGuire AL, Oliver JM, Slashinski MJ, Graves JL, Wang T, Kelly PA, Fisher W, Lau CC, Goss J, Okcu M, Treadwell-Deering D, Goldman AM, Noebels JL, Hilsenbeck SGGenetics in medicine : official journal of the American College of Medical GeneticsTo share or not to share: a randomized trial of consent for data sharing in genome research. Genet Med. 2011 Nov; 13(11):948-55.Genet Med2011-11-01T00:00:002011To share or not to share: a randomized trial of consent for data sharing in genome research.15833882Kong G, Kim HT, Wu K, DeNardo D, Hilsenbeck SG, Xu XC, Lamph WW, Bissonnette R, Dannenberg AJ, Brown PHCancer researchThe retinoid X receptor-selective retinoid, LGD1069, down-regulates cyclooxygenase-2 expression in human breast cells through transcription factor crosstalk: implications for molecular-based chemoprevention. Cancer Res. 2005 Apr 15; 65(8):3462-9.Cancer Res2005-04-15T00:00:002005The retinoid X receptor-selective retinoid, LGD1069, down-regulates cyclooxygenase-2 expression in human breast cells through transcription factor crosstalk: implications for molecular-based chemoprevention.15837971Arpino G, Weiss HL, Clark GM, Hilsenbeck SG, Osborne CKJournal of clinical oncology : official journal of the American Society of Clinical OncologyHormone receptor status of a contralateral breast cancer is independent of the receptor status of the first primary in patients not receiving adjuvant tamoxifen. J Clin Oncol. 2005 Jul 20; 23(21):4687-94.J Clin Oncol2005-04-18T00:00:002005Hormone receptor status of a contralateral breast cancer is independent of the receptor status of the first primary in patients not receiving adjuvant tamoxifen.22079032Fisher WE, Hodges SE, Wu MF, Hilsenbeck SG, Brunicardi FCAmerican journal of surgeryAssessment of the learning curve for pancreaticoduodenectomy. Am J Surg. 2012 Jun; 203(6):684-90.Am J Surg2011-11-09T00:00:002011Assessment of the learning curve for pancreaticoduodenectomy.16826579Tham YL, Sexton K, Kramer R, Hilsenbeck S, Elledge RCancerPrimary breast cancer phenotypes associated with propensity for central nervous system metastases. Cancer. 2006 Aug 15; 107(4):696-704.Cancer2006-08-15T00:00:002006Primary breast cancer phenotypes associated with propensity for central nervous system metastases.1953056Petru E, Sevin BU, Averette HE, Koechli OR, Hilsenbeck SArchives of gynecology and obstetricsLong-term survival in stage III and IV ovarian cancer. Arch Gynecol Obstet. 1991; 249(2):87-93.Arch Gynecol Obstet1991-01-01T00:00:001991Long-term survival in stage III and IV ovarian cancer.22213783Oliver JM, Slashinski MJ, Wang T, Kelly PA, Hilsenbeck SG, McGuire ALPublic health genomicsBalancing the risks and benefits of genomic data sharing: genome research participants' perspectives. Public Health Genomics. 2012; 15(2):106-14.Public Health Genomics2011-12-30T00:00:002011Balancing the risks and benefits of genomic data sharing: genome research participants' perspectives.22560224York B, Reineke EL, Sagen JV, Nikolai BC, Zhou S, Louet JF, Chopra AR, Chen X, Reed G, Noebels J, Adesina AM, Yu H, Wong LJ, Tsimelzon A, Hilsenbeck S, Stevens RD, Wenner BR, Ilkayeva O, Xu J, Newgard CB, O'Malley BWCell metabolismAblation of steroid receptor coactivator-3 resembles the human CACT metabolic myopathy. Cell Metab. 2012 May 02; 15(5):752-63.Cell Metab2012-05-02T00:00:002012Ablation of steroid receptor coactivator-3 resembles the human CACT metabolic myopathy.22706629Cerne JZ, Zong L, Jelinek J, Hilsenbeck SG, Wang T, Oesterreich S, McGuire SEBreast cancer research and treatmentBRCA1 promoter methylation status does not predict response to tamoxifen in sporadic breast cancer patients. Breast Cancer Res Treat. 2012 Aug; 135(1):135-43.Breast Cancer Res Treat2012-06-16T00:00:002012BRCA1 promoter methylation status does not predict response to tamoxifen in sporadic breast cancer patients.17121432Huang S, Podsypanina K, Chen Y, Cai W, Tsimelzon A, Hilsenbeck S, Li YTechnology in cancer research & treatmentWnt-1 is dominant over neu in specifying mammary tumor expression profiles. Technol Cancer Res Treat. 2006 Dec; 5(6):565-71.Technol Cancer Res Treat2006-12-01T00:00:002006Wnt-1 is dominant over neu in specifying mammary tumor expression profiles.17178900Kim HT, Kong G, Denardo D, Li Y, Uray I, Pal S, Mohsin S, Hilsenbeck SG, Bissonnette R, Lamph WW, Johnson K, Brown PHCancer researchIdentification of biomarkers modulated by the rexinoid LGD1069 (bexarotene) in human breast cells using oligonucleotide arrays. Cancer Res. 2006 Dec 15; 66(24):12009-18.Cancer Res2006-12-15T00:00:002006Identification of biomarkers modulated by the rexinoid LGD1069 (bexarotene) in human breast cells using oligonucleotide arrays.16322899Cleator S, Tsimelzon A, Ashworth A, Dowsett M, Dexter T, Powles T, Hilsenbeck S, Wong H, Osborne CK, O'Connell P, Chang JCBreast cancer research and treatmentGene expression patterns for doxorubicin (Adriamycin) and cyclophosphamide (cytoxan) (AC) response and resistance. Breast Cancer Res Treat. 2006 Feb; 95(3):229-33.Breast Cancer Res Treat2006-02-01T00:00:002006Gene expression patterns for doxorubicin (Adriamycin) and cyclophosphamide (cytoxan) (AC) response and resistance.23015261Smith CL, Migliaccio I, Chaubal V, Wu MF, Pace MC, Hartmaier R, Jiang S, Edwards DP, Guti?rrez MC, Hilsenbeck SG, Oesterreich SBreast cancer research and treatmentElevated nuclear expression of the SMRT corepressor in breast cancer is associated with earlier tumor recurrence. Breast Cancer Res Treat. 2012 Nov; 136(1):253-65.Breast Cancer Res Treat2012-09-27T00:00:002012Elevated nuclear expression of the SMRT corepressor in breast cancer is associated with earlier tumor recurrence.16467123Hilsenbeck SG, Osborne CKClinical cancer research : an official journal of the American Association for Cancer ResearchIs there a role for adjuvant tamoxifen in progesterone receptor-positive breast cancer? An in silico clinical trial. Clin Cancer Res. 2006 Feb 01; 12(3 Pt 2):1049s-1055s.Clin Cancer Res2006-02-01T00:00:002006Is there a role for adjuvant tamoxifen in progesterone receptor-positive breast cancer? An in silico clinical trial.23582504Wolfswinkel EM, Lopez SN, Weathers WM, Qashqai S, Wang T, Hilsenbeck SG, Rimawi MF, Heller LJournal of plastic, reconstructive & aesthetic surgery : JPRASPredictors of post-mastectomy reconstruction in an underserved population. J Plast Reconstr Aesthet Surg. 2013 Jun; 66(6):763-9.J Plast Reconstr Aesthet Surg2013-04-10T00:00:002013Predictors of post-mastectomy reconstruction in an underserved population.23730403George SK, Tovar-Sepulveda V, Shen SS, Jian W, Zhang Y, Hilsenbeck SG, Lerner SP, Smith CLTranslational oncologyChemoprevention of BBN-Induced Bladder Carcinogenesis by the Selective Estrogen Receptor Modulator Tamoxifen. Transl Oncol. 2013 Jun; 6(3):244-55.Transl Oncol2013-06-01T00:00:002013Chemoprevention of BBN-Induced Bladder Carcinogenesis by the Selective Estrogen Receptor Modulator Tamoxifen.27791031Fu X, Jeselsohn R, Pereira R, Hollingsworth EF, Creighton CJ, Li F, Shea M, Nardone A, De Angelis C, Heiser LM, Anur P, Wang N, Grasso CS, Spellman PT, Griffith OL, Tsimelzon A, Gutierrez C, Huang S, Edwards DP, Trivedi MV, Rimawi MF, Lopez-Terrada D, Hilsenbeck SG, Gray JW, Brown M, Osborne CK, Schiff RProceedings of the National Academy of Sciences of the United States of AmericaFOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer. Proc Natl Acad Sci U S A. 2016 10 25; 113(43):E6600-E6609.Proc Natl Acad Sci U S A2016-10-06T00:00:002016FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer.1957838Sridhar KS, Raub W, Duncan RC, Hilsenbeck S, Richman SPAmerican journal of clinical oncologyLung carcinoma in 1,336 patients. Am J Clin Oncol. 1991 Dec; 14(6):496-508.Am J Clin Oncol1991-12-01T00:00:001991Lung carcinoma in 1,336 patients.16912207Massarweh S, Osborne CK, Jiang S, Wakeling AE, Rimawi M, Mohsin SK, Hilsenbeck S, Schiff RCancer researchMechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer. Cancer Res. 2006 Aug 15; 66(16):8266-73.Cancer Res2006-08-15T00:00:002006Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer.16951220Nguyen DM, Sam K, Tsimelzon A, Li X, Wong H, Mohsin S, Clark GM, Hilsenbeck SG, Elledge RM, Allred DC, O'Connell P, Chang JCClinical cancer research : an official journal of the American Association for Cancer ResearchMolecular heterogeneity of inflammatory breast cancer: a hyperproliferative phenotype. Clin Cancer Res. 2006 Sep 01; 12(17):5047-54.Clin Cancer Res2006-09-01T00:00:002006Molecular heterogeneity of inflammatory breast cancer: a hyperproliferative phenotype.Authorship 5132152317938840Yee RW, Sperling HG, Kattek A, Paukert MT, Dawson K, Garcia M, Hilsenbeck SThe ocular surfaceIsolation of the ocular surface to treat dysfunctional tear syndrome associated with computer use. Ocul Surf. 2007 Oct; 5(4):308-15.Ocul Surf2007-10-01T00:00:002007Isolation of the ocular surface to treat dysfunctional tear syndrome associated with computer use.17287253Moraes RC, Zhang X, Harrington N, Fung JY, Wu MF, Hilsenbeck SG, Allred DC, Lewis MTDevelopment (Cambridge, England)Constitutive activation of smoothened (SMO) in mammary glands of transgenic mice leads to increased proliferation, altered differentiation and ductal dysplasia. Development. 2007 Mar; 134(6):1231-42.Development2007-02-07T00:00:002007Constitutive activation of smoothened (SMO) in mammary glands of transgenic mice leads to increased proliferation, altered differentiation and ductal dysplasia.17545528Herynk MH, Parra I, Cui Y, Beyer A, Wu MF, Hilsenbeck SG, Fuqua SAClinical cancer research : an official journal of the American Association for Cancer ResearchAssociation between the estrogen receptor alpha A908G mutation and outcomes in invasive breast cancer. Clin Cancer Res. 2007 Jun 01; 13(11):3235-43.Clin Cancer Res2007-06-01T00:00:002007Association between the estrogen receptor alpha A908G mutation and outcomes in invasive breast cancer.Authorship 100090518563554Zhang X, Harrington N, Moraes RC, Wu MF, Hilsenbeck SG, Lewis MTBreast cancer research and treatmentCyclopamine inhibition of human breast cancer cell growth independent of Smoothened (Smo). Breast Cancer Res Treat. 2009 Jun; 115(3):505-21.Breast Cancer Res Treat2008-06-19T00:00:002008Cyclopamine inhibition of human breast cancer cell growth independent of Smoothened (Smo).18273671Fisher WE, Chai C, Hodges SE, Wu MF, Hilsenbeck SG, Brunicardi FCJournal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary TractEffect of BioGlue on the incidence of pancreatic fistula following pancreas resection. J Gastrointest Surg. 2008 May; 12(5):882-90.J Gastrointest Surg2008-02-14T00:00:002008Effect of BioGlue on the incidence of pancreatic fistula following pancreas resection.18445819Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, Wu MF, Hilsenbeck SG, Pavlick A, Zhang X, Chamness GC, Wong H, Rosen J, Chang JCJournal of the National Cancer InstituteIntrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst. 2008 May 07; 100(9):672-9.J Natl Cancer Inst2008-04-29T00:00:002008Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy.18498873Shah D, Fisher WE, Hodges SE, Wu MF, Hilsenbeck SG, Charles Brunicardi FThe Journal of surgical researchPreoperative prediction of complete resection in pancreatic cancer. J Surg Res. 2008 Jun 15; 147(2):216-20.J Surg Res2008-03-26T00:00:002008Preoperative prediction of complete resection in pancreatic cancer.18787212Siwko SK, Dong J, Lewis MT, Liu H, Hilsenbeck SG, Li YStem cells (Dayton, Ohio)Evidence that an early pregnancy causes a persistent decrease in the number of functional mammary epithelial stem cells--implications for pregnancy-induced protection against breast cancer. Stem Cells. 2008 Dec; 26(12):3205-9.Stem Cells2008-09-11T00:00:002008Evidence that an early pregnancy causes a persistent decrease in the number of functional mammary epithelial stem cells--implications for pregnancy-induced protection against breast cancer.18794137Creighton CJ, Massarweh S, Huang S, Tsimelzon A, Hilsenbeck SG, Osborne CK, Shou J, Malorni L, Schiff RCancer researchDevelopment of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts. Cancer Res. 2008 Sep 15; 68(18):7493-501.Cancer Res2008-09-15T00:00:002008Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts.19117983Ochsner SA, Steffen DL, Hilsenbeck SG, Chen ES, Watkins C, McKenna NJCancer researchGEMS (Gene Expression MetaSignatures), a Web resource for querying meta-analysis of expression microarray datasets: 17beta-estradiol in MCF-7 cells. Cancer Res. 2009 Jan 01; 69(1):23-6.Cancer Res2009-01-01T00:00:002009GEMS (Gene Expression MetaSignatures), a Web resource for querying meta-analysis of expression microarray datasets: 17beta-estradiol in MCF-7 cells.19141783Strecker TE, Shen Q, Zhang Y, Hill JL, Li Y, Wang C, Kim HT, Gilmer TM, Sexton KR, Hilsenbeck SG, Osborne CK, Brown PHJournal of the National Cancer InstituteEffect of lapatinib on the development of estrogen receptor-negative mammary tumors in mice. J Natl Cancer Inst. 2009 Jan 21; 101(2):107-13.J Natl Cancer Inst2009-01-13T00:00:002009Effect of lapatinib on the development of estrogen receptor-negative mammary tumors in mice.19174577Medina D, Kittrell F, Hill J, Zhang Y, Hilsenbeck SG, Bissonette R, Brown PHCancer prevention research (Philadelphia, Pa.)Prevention of tumorigenesis in p53-null mammary epithelium by rexinoid bexarotene, tyrosine kinase inhibitor gefitinib, and celecoxib. Cancer Prev Res (Phila). 2009 Feb; 2(2):168-74.Cancer Prev Res (Phila)2009-01-27T00:00:002009Prevention of tumorigenesis in p53-null mammary epithelium by rexinoid bexarotene, tyrosine kinase inhibitor gefitinib, and celecoxib.Authorship 100200319137425Hammerich-Hille S, Bardout VJ, Hilsenbeck SG, Osborne CK, Oesterreich SBreast cancer research and treatmentLow SAFB levels are associated with worse outcome in breast cancer patients. Breast Cancer Res Treat. 2010 Jun; 121(2):503-9.Breast Cancer Res Treat2009-01-10T00:00:002009Low SAFB levels are associated with worse outcome in breast cancer patients.19495957Wu MF, Hilsenbeck SG, Tham YL, Kramer R, Elledge RM, Chang JC, Friedman LCBreast cancer research and treatmentThe efficacy of sertraline for controlling hot flashes in women with or at high risk of developing breast cancer. Breast Cancer Res Treat. 2009 Nov; 118(2):369-75.Breast Cancer Res Treat2009-06-03T00:00:002009The efficacy of sertraline for controlling hot flashes in women with or at high risk of developing breast cancer.19533338De Amicis F, Thirugnansampanthan J, Cui Y, Selever J, Beyer A, Parra I, Weigel NL, Herynk MH, Tsimelzon A, Lewis MT, Chamness GC, Hilsenbeck SG, And? S, Fuqua SABreast cancer research and treatmentAndrogen receptor overexpression induces tamoxifen resistance in human breast cancer cells. Breast Cancer Res Treat. 2010 May; 121(1):1-11.Breast Cancer Res Treat2009-06-17T00:00:002009Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells.19666588Creighton CJ, Li X, Landis M, Dixon JM, Neumeister VM, Sjolund A, Rimm DL, Wong H, Rodriguez A, Herschkowitz JI, Fan C, Zhang X, He X, Pavlick A, Gutierrez MC, Renshaw L, Larionov AA, Faratian D, Hilsenbeck SG, Perou CM, Lewis MT, Rosen JM, Chang JCProceedings of the National Academy of Sciences of the United States of AmericaResidual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci U S A. 2009 Aug 18; 106(33):13820-5.Proc Natl Acad Sci U S A2009-08-03T00:00:002009Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features.19808870Speers C, Tsimelzon A, Sexton K, Herrick AM, Gutierrez C, Culhane A, Quackenbush J, Hilsenbeck S, Chang J, Brown PClinical cancer research : an official journal of the American Association for Cancer ResearchIdentification of novel kinase targets for the treatment of estrogen receptor-negative breast cancer. Clin Cancer Res. 2009 Oct 15; 15(20):6327-40.Clin Cancer Res2009-10-06T00:00:002009Identification of novel kinase targets for the treatment of estrogen receptor-negative breast cancer.2243256Hilsenbeck SGJournal of clinical epidemiologyQuality control practices in centralized tumor registries in North America. J Clin Epidemiol. 1990; 43(11):1201-12.J Clin Epidemiol1990-01-01T00:00:001990Quality control practices in centralized tumor registries in North America.19909553Chang CC, Zhou X, Taylor JJ, Huang WT, Ren X, Monzon F, Feng Y, Rao PH, Lu XY, Fabio F, Hilsenbeck S, Creighton CJ, Jaffe ES, Lau CCJournal of hematology & oncologyGenomic profiling of plasmablastic lymphoma using array comparative genomic hybridization (aCGH): revealing significant overlapping genomic lesions with diffuse large B-cell lymphoma. J Hematol Oncol. 2009 Nov 12; 2:47.J Hematol Oncol2009-11-12T00:00:002009Genomic profiling of plasmablastic lymphoma using array comparative genomic hybridization (aCGH): revealing significant overlapping genomic lesions with diffuse large B-cell lymphoma.19920204Chen L, Mayer JA, Krisko TI, Speers CW, Wang T, Hilsenbeck SG, Brown PHCancer researchInhibition of the p38 kinase suppresses the proliferation of human ER-negative breast cancer cells. Cancer Res. 2009 Dec 01; 69(23):8853-61.Cancer Res2009-11-17T00:00:002009Inhibition of the p38 kinase suppresses the proliferation of human ER-negative breast cancer cells.19998099McGuire AL, Diaz CM, Wang T, Hilsenbeck SGThe American journal of bioethics : AJOBSocial networkers' attitudes toward direct-to-consumer personal genome testing. Am J Bioeth. 2009; 9(6-7):3-10.Am J Bioeth2009-01-01T00:00:002009Social networkers' attitudes toward direct-to-consumer personal genome testing.Authorship 100746420422750Sweeney AD, Fisher WE, Wu MF, Hilsenbeck SG, Brunicardi FCThe Journal of surgical researchValue of pancreatic resection for cancer metastatic to the pancreas. J Surg Res. 2010 May 15; 160(2):268-76.J Surg Res2010-05-15T00:00:002010Value of pancreatic resection for cancer metastatic to the pancreas.20443866Moran A, Tsimelzon AI, Mastrangelo MA, Wu Y, Yu B, Hilsenbeck SG, Poli V, Tweardy DJClinical and translational sciencePrevention of trauma/hemorrhagic shock-induced lung apoptosis by IL-6-mediated activation of Stat3. Clin Transl Sci. 2009 Feb; 2(1):41-9.Clin Transl Sci2009-02-01T00:00:002009Prevention of trauma/hemorrhagic shock-induced lung apoptosis by IL-6-mediated activation of Stat3.20501844Pond AC, Herschkowitz JI, Schwertfeger KL, Welm B, Zhang Y, York B, Cardiff RD, Hilsenbeck S, Perou CM, Creighton CJ, Lloyd RE, Rosen JMCancer researchFibroblast growth factor receptor signaling dramatically accelerates tumorigenesis and enhances oncoprotein translation in the mouse mammary tumor virus-Wnt-1 mouse model of breast cancer. Cancer Res. 2010 Jun 15; 70(12):4868-79.Cancer Res2010-05-25T00:00:002010Fibroblast growth factor receptor signaling dramatically accelerates tumorigenesis and enhances oncoprotein translation in the mouse mammary tumor virus-Wnt-1 mouse model of breast cancer.21138857Rimawi MF, Wiechmann LS, Wang YC, Huang C, Migliaccio I, Wu MF, Gutierrez C, Hilsenbeck SG, Arpino G, Massarweh S, Ward R, Soliz R, Osborne CK, Schiff RClinical cancer research : an official journal of the American Association for Cancer ResearchReduced dose and intermittent treatment with lapatinib and trastuzumab for potent blockade of the HER pathway in HER2/neu-overexpressing breast tumor xenografts. Clin Cancer Res. 2011 Mar 15; 17(6):1351-61.Clin Cancer Res2010-12-07T00:00:002010Reduced dose and intermittent treatment with lapatinib and trastuzumab for potent blockade of the HER pathway in HER2/neu-overexpressing breast tumor xenografts.2306183Moffat FL, Ketcham AS, Robinson DS, Legaspi A, Ghandur-Mnaymneh L, Hilsenbeck SArchives of surgery (Chicago, Ill. : 1960)Segmental mastectomy without radiotherapy for T1 and small T2 breast carcinomas. Arch Surg. 1990 Mar; 125(3):364-9.Arch Surg1990-03-01T00:00:001990Segmental mastectomy without radiotherapy for T1 and small T2 breast carcinomas.2387533Petru E, Sevin BU, Averette HE, Koechli OR, Perras JP, Hilsenbeck SGynecologic oncologyComparison of three tumor markers--CA-125, lipid-associated sialic acid (LSA), and NB/70K--in monitoring ovarian cancer. Gynecol Oncol. 1990 Aug; 38(2):181-6.Gynecol Oncol1990-08-01T00:00:001990Comparison of three tumor markers--CA-125, lipid-associated sialic acid (LSA), and NB/70K--in monitoring ovarian cancer.Authorship 1009864Authorship 7291701320815856Moskovic DJ, Hodges SE, Wu MF, Brunicardi FC, Hilsenbeck SG, Fisher WEHPB : the official journal of the International Hepato Pancreato Biliary AssociationDrain data to predict clinically relevant pancreatic fistula. HPB (Oxford). 2010 Sep; 12(7):472-81.HPB (Oxford)2010-09-01T00:00:002010Drain data to predict clinically relevant pancreatic fistula.20860838McHenry PR, Sears JC, Herrick MP, Chang P, Heckman-Stoddard BM, Rybarczyk M, Chodosh LA, Gunther EJ, Hilsenbeck SG, Rosen JM, Vargo-Gogola TBreast cancer research : BCRP190B RhoGAP has pro-tumorigenic functions during MMTV-Neu mammary tumorigenesis and metastasis. Breast Cancer Res. 2010; 12(5):R73.Breast Cancer Res2010-09-22T00:00:002010P190B RhoGAP has pro-tumorigenic functions during MMTV-Neu mammary tumorigenesis and metastasis.28196254Nangia J, Wang T, Osborne C, Niravath P, Otte K, Papish S, Holmes F, Abraham J, Lacouture M, Courtright J, Paxman R, Rude M, Hilsenbeck S, Osborne CK, Rimawi MJAMAEffect of a Scalp Cooling Device on Alopecia in Women Undergoing Chemotherapy for Breast Cancer: The SCALP Randomized Clinical Trial. JAMA. 2017 02 14; 317(6):596-605.JAMA2017-02-14T00:00:002017Effect of a Scalp Cooling Device on Alopecia in Women Undergoing Chemotherapy for Breast Cancer: The SCALP Randomized Clinical Trial.21867536Dearth RK, Kuiatse I, Wang YF, Liao L, Hilsenbeck SG, Brown PH, Xu J, Lee AVBMC cancerA moderate elevation of circulating levels of IGF-I does not alter ErbB2 induced mammary tumorigenesis. BMC Cancer. 2011 Aug 25; 11:377.BMC Cancer2011-08-25T00:00:002011A moderate elevation of circulating levels of IGF-I does not alter ErbB2 induced mammary tumorigenesis.21884573Huang C, Park CC, Hilsenbeck SG, Ward R, Rimawi MF, Wang YC, Shou J, Bissell MJ, Osborne CK, Schiff RBreast cancer research : BCR?1 integrin mediates an alternative survival pathway in breast cancer cells resistant to lapatinib. Breast Cancer Res. 2011 Aug 31; 13(4):R84.Breast Cancer Res2011-08-31T00:00:002011?1 integrin mediates an alternative survival pathway in breast cancer cells resistant to lapatinib.22215751Rimawi M, Hilsenbeck SGJournal of clinical oncology : official journal of the American Society of Clinical OncologyMaking sense of clinical trial data: is inverse probability of censoring weighted analysis the answer to crossover bias? J Clin Oncol. 2012 Feb 01; 30(4):453-8.J Clin Oncol2012-01-03T00:00:002012Making sense of clinical trial data: is inverse probability of censoring weighted analysis the answer to crossover bias?22261033Shan M, Yuan X, Song LZ, Roberts L, Zarinkamar N, Seryshev A, Zhang Y, Hilsenbeck S, Chang SH, Dong C, Corry DB, Kheradmand FScience translational medicineCigarette smoke induction of osteopontin (SPP1) mediates T(H)17 inflammation in human and experimental emphysema. Sci Transl Med. 2012 Jan 18; 4(117):117ra9.Sci Transl Med2012-01-18T00:00:002012Cigarette smoke induction of osteopontin (SPP1) mediates T(H)17 inflammation in human and experimental emphysema.21177763Litzenburger BC, Creighton CJ, Tsimelzon A, Chan BT, Hilsenbeck SG, Wang T, Carboni JM, Gottardis MM, Huang F, Chang JC, Lewis MT, Rimawi MF, Lee AVClinical cancer research : an official journal of the American Association for Cancer ResearchHigh IGF-IR activity in triple-negative breast cancer cell lines and tumorgrafts correlates with sensitivity to anti-IGF-IR therapy. Clin Cancer Res. 2011 Apr 15; 17(8):2314-27.Clin Cancer Res2010-12-22T00:00:002010High IGF-IR activity in triple-negative breast cancer cell lines and tumorgrafts correlates with sensitivity to anti-IGF-IR therapy.21390497Spears M, Oesterreich S, Migliaccio I, Guiterrez C, Hilsenbeck S, Quintayo MA, Pedraza J, Munro AF, Thomas JS, Kerr GR, Jack WJ, Kunkler IH, Cameron DA, Chetty U, Bartlett JMBreast cancer research and treatmentThe p160 ER co-regulators predict outcome in ER negative breast cancer. Breast Cancer Res Treat. 2012 Jan; 131(2):463-72.Breast Cancer Res Treat2011-03-09T00:00:002011The p160 ER co-regulators predict outcome in ER negative breast cancer.Authorship 7852331121465171Dhar SU, Cooper HP, Wang T, Parks B, Staggs SA, Hilsenbeck S, Plon SEBreast cancer research and treatmentSignificant differences among physician specialties in management recommendations of BRCA1 mutation carriers. Breast Cancer Res Treat. 2011 Aug; 129(1):221-7.Breast Cancer Res Treat2011-04-05T00:00:002011Significant differences among physician specialties in management recommendations of BRCA1 mutation carriers.22879872Dave B, Landis MD, Tweardy DJ, Chang JC, Dobrolecki LE, Wu MF, Zhang X, Westbrook TF, Hilsenbeck SG, Liu D, Lewis MTPloS oneSelective small molecule Stat3 inhibitor reduces breast cancer tumor-initiating cells and improves recurrence free survival in a human-xenograft model. PLoS One. 2012; 7(8):e30207.PLoS One2012-08-06T00:00:002012Selective small molecule Stat3 inhibitor reduces breast cancer tumor-initiating cells and improves recurrence free survival in a human-xenograft model.27869122Chaudhury A, Cheema S, Fachini JM, Kongchan N, Lu G, Simon LM, Wang T, Mao S, Rosen DG, Ittmann MM, Hilsenbeck SG, Shaw CA, Neilson JRNature communicationsCELF1 is a central node in post-transcriptional regulatory programmes underlying EMT. Nat Commun. 2016 11 21; 7:13362.Nat Commun2016-11-21T00:00:002016CELF1 is a central node in post-transcriptional regulatory programmes underlying EMT.21532625Bu W, Chen J, Morrison GD, Huang S, Creighton CJ, Huang J, Chamness GC, Hilsenbeck SG, Roop DR, Leavitt AD, Li YOncogeneKeratin 6a marks mammary bipotential progenitor cells that can give rise to a unique tumor model resembling human normal-like breast cancer. Oncogene. 2011 Oct 27; 30(43):4399-409.Oncogene2011-05-02T00:00:002011Keratin 6a marks mammary bipotential progenitor cells that can give rise to a unique tumor model resembling human normal-like breast cancer.23097355Pond AC, Bin X, Batts T, Roarty K, Hilsenbeck S, Rosen JMStem cells (Dayton, Ohio)Fibroblast growth factor receptor signaling is essential for normal mammary gland development and stem cell function. Stem Cells. 2013 Jan; 31(1):178-89.Stem Cells2013-01-01T00:00:002013Fibroblast growth factor receptor signaling is essential for normal mammary gland development and stem cell function.23124476Malorni L, Shetty PB, De Angelis C, Hilsenbeck S, Rimawi MF, Elledge R, Osborne CK, De Placido S, Arpino GBreast cancer research and treatmentClinical and biologic features of triple-negative breast cancers in a large cohort of patients with long-term follow-up. Breast Cancer Res Treat. 2012 Dec; 136(3):795-804.Breast Cancer Res Treat2012-11-04T00:00:002012Clinical and biologic features of triple-negative breast cancers in a large cohort of patients with long-term follow-up.21736749Daves MH, Hilsenbeck SG, Lau CC, Man TKBMC medical genomicsMeta-analysis of multiple microarray datasets reveals a common gene signature of metastasis in solid tumors. BMC Med Genomics. 2011 Jul 07; 4:56.BMC Med Genomics2011-07-07T00:00:002011Meta-analysis of multiple microarray datasets reveals a common gene signature of metastasis in solid tumors.21792626Massarweh S, Tham YL, Huang J, Sexton K, Weiss H, Tsimelzon A, Beyer A, Rimawi M, Cai WY, Hilsenbeck S, Fuqua S, Elledge RBreast cancer research and treatmentA phase II neoadjuvant trial of anastrozole, fulvestrant, and gefitinib in patients with newly diagnosed estrogen receptor positive breast cancer. Breast Cancer Res Treat. 2011 Oct; 129(3):819-27.Breast Cancer Res Treat2011-07-27T00:00:002011A phase II neoadjuvant trial of anastrozole, fulvestrant, and gefitinib in patients with newly diagnosed estrogen receptor positive breast cancer.23315938York B, Sagen JV, Tsimelzon A, Louet JF, Chopra AR, Reineke EL, Zhou S, Stevens RD, Wenner BR, Ilkayeva O, Bain JR, Xu J, Hilsenbeck SG, Newgard CB, O'Malley BWMolecular endocrinology (Baltimore, Md.)Research resource: tissue- and pathway-specific metabolomic profiles of the steroid receptor coactivator (SRC) family. Mol Endocrinol. 2013 Feb; 27(2):366-80.Mol Endocrinol2013-01-11T00:00:002013Research resource: tissue- and pathway-specific metabolomic profiles of the steroid receptor coactivator (SRC) family.23569315Rimawi MF, Mayer IA, Forero A, Nanda R, Goetz MP, Rodriguez AA, Pavlick AC, Wang T, Hilsenbeck SG, Gutierrez C, Schiff R, Osborne CK, Chang JCJournal of clinical oncology : official journal of the American Society of Clinical OncologyMulticenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006. J Clin Oncol. 2013 May 10; 31(14):1726-31.J Clin Oncol2013-04-08T00:00:002013Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006.22123186Wang YC, Morrison G, Gillihan R, Guo J, Ward RM, Fu X, Botero MF, Healy NA, Hilsenbeck SG, Phillips GL, Chamness GC, Rimawi MF, Osborne CK, Schiff RBreast cancer research : BCRDifferent mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers--role of estrogen receptor and HER2 reactivation. Breast Cancer Res. 2011; 13(6):R121.Breast Cancer Res2011-11-28T00:00:002011Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers--role of estrogen receptor and HER2 reactivation.Authorship 1020896Authorship 840956328224382Gastelum GM, Iqbal C, Hilsenbeck SG, Rimawi MF, Niravath PBreast cancer research and treatmentRetrospective review of genomic testing in breast cancer: Does it improve outcome? Breast Cancer Res Treat. 2017 May; 163(1):191-195.Breast Cancer Res Treat2017-02-21T00:00:002017Retrospective review of genomic testing in breast cancer: Does it improve outcome?22695491Xu J, Shetty PB, Feng W, Chenault C, Bast RC, Issa JP, Hilsenbeck SG, Yu YBMC cancerMethylation of HIN-1, RASSF1A, RIL and CDH13 in breast cancer is associated with clinical characteristics, but only RASSF1A methylation is associated with outcome. BMC Cancer. 2012 Jun 13; 12:243.BMC Cancer2012-06-13T00:00:002012Methylation of HIN-1, RASSF1A, RIL and CDH13 in breast cancer is associated with clinical characteristics, but only RASSF1A methylation is associated with outcome.2966667Davila E, Vogel CL, East D, Cairns V, Hilsenbeck SCancerClinical trial of high-dose oral medroxyprogesterone acetate in the treatment of metastatic breast cancer and review of the literature. Cancer. 1988 Jun 01; 61(11):2161-7.Cancer1988-06-01T00:00:001988Clinical trial of high-dose oral medroxyprogesterone acetate in the treatment of metastatic breast cancer and review of the literature.7696176Reddy KB, Yee D, Hilsenbeck SG, Coffey RJ, Osborne CKCell growth & differentiation : the molecular biology journal of the American Association for Cancer ResearchInhibition of estrogen-induced breast cancer cell proliferation by reduction in autocrine transforming growth factor alpha expression. Cell Growth Differ. 1994 Dec; 5(12):1275-82.Cell Growth Differ1994-12-01T00:00:001994Inhibition of estrogen-induced breast cancer cell proliferation by reduction in autocrine transforming growth factor alpha expression.7819579Clark GM, Hilsenbeck SG, Ravdin PM, De Laurentiis M, Osborne CKBreast cancer research and treatmentPrognostic factors: rationale and methods of analysis and integration. Breast Cancer Res Treat. 1994; 32(1):105-12.Breast Cancer Res Treat1994-01-01T00:00:001994Prognostic factors: rationale and methods of analysis and integration.8180781Schneider BG, Hilsenbeck SG, Hensel CH, Pekkel V, Shelton CH, Rodr?guez-Mart?nez HA, Guti?rrez-D?az ME, Pulitzer DR, Allred DCVirchows Archiv : an international journal of pathologyp53 mutations in gastric and colorectal cancers in Texas Hispanics versus Anglos. Virchows Arch. 1994; 424(2):187-93.Virchows Arch1994-01-01T00:00:001994p53 mutations in gastric and colorectal cancers in Texas Hispanics versus Anglos.8222804Kroenke K, Lawrence VA, Theroux JF, Tuley MR, Hilsenbeck SChestPostoperative complications after thoracic and major abdominal surgery in patients with and without obstructive lung disease. Chest. 1993 Nov; 104(5):1445-51.Chest1993-11-01T00:00:001993Postoperative complications after thoracic and major abdominal surgery in patients with and without obstructive lung disease.8402609Oesterreich S, Weng CN, Qiu M, Hilsenbeck SG, Osborne CK, Fuqua SACancer researchThe small heat shock protein hsp27 is correlated with growth and drug resistance in human breast cancer cell lines. Cancer Res. 1993 Oct 01; 53(19):4443-8.Cancer Res1993-10-01T00:00:001993The small heat shock protein hsp27 is correlated with growth and drug resistance in human breast cancer cell lines.8614741Hilsenbeck SG, Clark GMStatistics in medicinePractical p-value adjustment for optimally selected cutpoints. Stat Med. 1996 Jan 15; 15(1):103-12.Stat Med1996-01-15T00:00:001996Practical p-value adjustment for optimally selected cutpoints.8648367Rothenberg ML, Eckardt JR, Kuhn JG, Burris HA, Nelson J, Hilsenbeck SG, Rodriguez GI, Thurman AM, Smith LS, Eckhardt SG, Weiss GR, Elfring GL, Rinaldi DA, Schaaf LJ, Von Hoff DDJournal of clinical oncology : official journal of the American Society of Clinical OncologyPhase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol. 1996 Apr; 14(4):1128-35.J Clin Oncol1996-04-01T00:00:001996Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer.Authorship 86960328Authorship 8698761428487443Xu X, De Angelis C, Burke KA, Nardone A, Hu H, Qin L, Veeraraghavan J, Sethunath V, Heiser LM, Wang N, Ng CKY, Chen ES, Renwick A, Wang T, Nanda S, Shea M, Mitchell T, Rajendran M, Waters I, Zabransky DJ, Scott KL, Gutierrez C, Nagi C, Geyer FC, Chamness GC, Park BH, Shaw CA, Hilsenbeck SG, Rimawi MF, Gray JW, Weigelt B, Reis-Filho JS, Osborne CK, Schiff RClinical cancer research : an official journal of the American Association for Cancer ResearchHER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer. Clin Cancer Res. 2017 Sep 01; 23(17):5123-5134.Clin Cancer Res2017-05-09T00:00:002017HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer.28515148Elsarraj HS, Valdez KE, Hong Y, Grimm SL, Ricci LR, Fan F, Tawfik O, May L, Cusick T, Inciardi M, Redick M, Gatewood J, Winblad O, Hilsenbeck S, Edwards DP, Hagan CR, Godwin AK, Fabian C, Behbod FCancer researchNEMO, a Transcriptional Target of Estrogen and Progesterone, Is Linked to Tumor Suppressor PML in Breast Cancer. Cancer Res. 2017 07 15; 77(14):3802-3813.Cancer Res2017-05-17T00:00:002017NEMO, a Transcriptional Target of Estrogen and Progesterone, Is Linked to Tumor Suppressor PML in Breast Cancer.Authorship 103536129473217Rodriguez GI, Kuhn JG, Weiss GR, Hilsenbeck SG, Eckardt JR, Thurman A, Rinaldi DA, Hodges S, Von Hoff DD, Rowinsky EKBloodA bioavailability and pharmacokinetic study of oral and intravenous hydroxyurea. Blood. 1998 Mar 01; 91(5):1533-41.Blood1998-03-01T00:00:001998A bioavailability and pharmacokinetic study of oral and intravenous hydroxyurea.9516083Lee AV, Hilsenbeck SG, Yee DBreast cancer research and treatmentIGF system components as prognostic markers in breast cancer. Breast Cancer Res Treat. 1998 Feb; 47(3):295-302.Breast Cancer Res Treat1998-02-01T00:00:001998IGF system components as prognostic markers in breast cancer.9688014Revankar SG, Kirkpatrick WR, McAtee RK, Dib OP, Fothergill AW, Redding SW, Rinaldi MG, Hilsenbeck SG, Patterson TFThe American journal of medicineA randomized trial of continuous or intermittent therapy with fluconazole for oropharyngeal candidiasis in HIV-infected patients: clinical outcomes and development of fluconazole resistance. Am J Med. 1998 Jul; 105(1):7-11.Am J Med1998-07-01T00:00:001998A randomized trial of continuous or intermittent therapy with fluconazole for oropharyngeal candidiasis in HIV-infected patients: clinical outcomes and development of fluconazole resistance.9735415Gazitt Y, Rothenberg ML, Hilsenbeck SG, Fey V, Thomas C, Montegomrey WInternational journal of oncologyBcl-2 overexpression is associated with resistance to paclitaxel, but not gemcitabine, in multiple myeloma cells. Int J Oncol. 1998 Oct; 13(4):839-48.Int J Oncol1998-10-01T00:00:001998Bcl-2 overexpression is associated with resistance to paclitaxel, but not gemcitabine, in multiple myeloma cells.9740545Rodriguez GI, Kuhn JG, Weiss G, De La Cruz P, New P, Fields SM, Eckardt JR, Campbell L, Clark GM, Hilsenbeck SG, Von Hoff DDInvestigational new drugsA phase I and pharmacokinetic trial of terephthalamidine (NSC 57155) as a 120-hour continuous infusion. Invest New Drugs. 1998; 16(1):57-67.Invest New Drugs1998-01-01T00:00:001998A phase I and pharmacokinetic trial of terephthalamidine (NSC 57155) as a 120-hour continuous infusion.9815913Elledge RM, Lock-Lim S, Allred DC, Hilsenbeck SG, Cordner LClinical cancer research : an official journal of the American Association for Cancer Researchp53 mutation and tamoxifen resistance in breast cancer. Clin Cancer Res. 1995 Oct; 1(10):1203-8.Clin Cancer Res1995-10-01T00:00:001995p53 mutation and tamoxifen resistance in breast cancer.9816207Brown RW, Allred CD, Clark GM, Osborne CK, Hilsenbeck SGClinical cancer research : an official journal of the American Association for Cancer ResearchPrognostic value of Ki-67 compared to S-phase fraction in axillary node-negative breast cancer. Clin Cancer Res. 1996 Mar; 2(3):585-92.Clin Cancer Res1996-03-01T00:00:001996Prognostic value of Ki-67 compared to S-phase fraction in axillary node-negative breast cancer.10100596Weitman S, Mangold G, Marty J, Dexter D, Hilsenbeck S, Rake J, Juniewicz P, Von Hoff DCancer chemotherapy and pharmacologyEvidence of enhanced in vivo activity using tirapazamine with paclitaxel and paraplatin regimens against the MV-522 human lung cancer xenograft. Cancer Chemother Pharmacol. 1999; 43(5):402-8.Cancer Chemother Pharmacol1999-01-01T00:00:001999Evidence of enhanced in vivo activity using tirapazamine with paclitaxel and paraplatin regimens against the MV-522 human lung cancer xenograft.1391991Knorr KL, Hilsenbeck SG, Wenger CR, Pounds G, Oldaker T, Vendely P, Pandian MR, Harrington D, Clark GMBreast cancer research and treatmentMaking the most of your prognostic factors: presenting a more accurate survival model for breast cancer patients. Breast Cancer Res Treat. 1992; 22(3):251-62.Breast Cancer Res Treat1992-01-01T00:00:001992Making the most of your prognostic factors: presenting a more accurate survival model for breast cancer patients.10319328Lee AV, Jackson JG, Gooch JL, Hilsenbeck SG, Coronado-Heinsohn E, Osborne CK, Yee DMolecular endocrinology (Baltimore, Md.)Enhancement of insulin-like growth factor signaling in human breast cancer: estrogen regulation of insulin receptor substrate-1 expression in vitro and in vivo. Mol Endocrinol. 1999 May; 13(5):787-96.Mol Endocrinol1999-05-01T00:00:001999Enhancement of insulin-like growth factor signaling in human breast cancer: estrogen regulation of insulin receptor substrate-1 expression in vitro and in vivo.10327037Diab SG, Hilsenbeck SG, Izbicka E, Weitman SD, Von Hoff DDAnti-cancer drugsSignificant activity of a novel cytotoxic agent, LY295501, against a wide range of tumors in the human tumor cloning system. Anticancer Drugs. 1999 Mar; 10(3):303-7.Anticancer Drugs1999-03-01T00:00:001999Significant activity of a novel cytotoxic agent, LY295501, against a wide range of tumors in the human tumor cloning system.Authorship 103771010405442Cody JD, Ghidoni PD, DuPont BR, Hale DE, Hilsenbeck SG, Stratton RF, Hoffman DS, Muller S, Schaub RL, Leach RJ, Kaye CIAmerican journal of medical geneticsCongenital anomalies and anthropometry of 42 individuals with deletions of chromosome 18q. Am J Med Genet. 1999 Aug 27; 85(5):455-62.Am J Med Genet1999-08-27T00:00:001999Congenital anomalies and anthropometry of 42 individuals with deletions of chromosome 18q.10561295Jatoi I, Hilsenbeck SG, Clark GM, Osborne CKJournal of clinical oncology : official journal of the American Society of Clinical OncologySignificance of axillary lymph node metastasis in primary breast cancer. J Clin Oncol. 1999 Aug; 17(8):2334-40.J Clin Oncol1999-08-01T00:00:001999Significance of axillary lymph node metastasis in primary breast cancer.Authorship 872736828604738Neelakantan D, Zhou H, Oliphant MUJ, Zhang X, Simon LM, Henke DM, Shaw CA, Wu MF, Hilsenbeck SG, White LD, Lewis MT, Ford HLNature communicationsEMT cells increase breast cancer metastasis via paracrine GLI activation in neighbouring tumour cells. Nat Commun. 2017 06 12; 8:15773.Nat Commun2017-06-12T00:00:002017EMT cells increase breast cancer metastasis via paracrine GLI activation in neighbouring tumour cells.Authorship 874628328465075Guven A, Villares GJ, Hilsenbeck SG, Lewis A, Landua JD, Dobrolecki LE, Wilson LJ, Lewis MTActa biomaterialiaCarbon nanotube capsules enhance the in vivo efficacy of cisplatin. Acta Biomater. 2017 08; 58:466-478.Acta Biomater2017-05-02T00:00:002017Carbon nanotube capsules enhance the in vivo efficacy of cisplatin.14679152Lu C, Speers C, Zhang Y, Xu X, Hill J, Steinbis E, Celestino J, Shen Q, Kim H, Hilsenbeck S, Mohsin SK, Wakeling A, Osborne CK, Brown PHJournal of the National Cancer InstituteEffect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors. J Natl Cancer Inst. 2003 Dec 17; 95(24):1825-33.J Natl Cancer Inst2003-12-17T00:00:002003Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors.15692760Jatoi I, Tsimelzon A, Weiss H, Clark GM, Hilsenbeck SGBreast cancer research and treatmentHazard rates of recurrence following diagnosis of primary breast cancer. Breast Cancer Res Treat. 2005 Jan; 89(2):173-8.Breast Cancer Res Treat2005-01-01T00:00:002005Hazard rates of recurrence following diagnosis of primary breast cancer.15710948Mohsin SK, Weiss HL, Gutierrez MC, Chamness GC, Schiff R, Digiovanna MP, Wang CX, Hilsenbeck SG, Osborne CK, Allred DC, Elledge R, Chang JCJournal of clinical oncology : official journal of the American Society of Clinical OncologyNeoadjuvant trastuzumab induces apoptosis in primary breast cancers. J Clin Oncol. 2005 Apr 10; 23(11):2460-8.J Clin Oncol2005-02-14T00:00:002005Neoadjuvant trastuzumab induces apoptosis in primary breast cancers.16027729Lu C, Shen Q, DuPr? E, Kim H, Hilsenbeck S, Brown PHOncogenecFos is critical for MCF-7 breast cancer cell growth. Oncogene. 2005 Sep 29; 24(43):6516-24.Oncogene2005-09-29T00:00:002005cFos is critical for MCF-7 breast cancer cell growth.16236516Osborne CK, Schiff R, Arpino G, Lee AS, Hilsenbeck VGBreast (Edinburgh, Scotland)Endocrine responsiveness: understanding how progesterone receptor can be used to select endocrine therapy. Breast. 2005 Dec; 14(6):458-65.Breast2005-10-19T00:00:002005Endocrine responsiveness: understanding how progesterone receptor can be used to select endocrine therapy.16282442Behbod F, Xian W, Shaw CA, Hilsenbeck SG, Tsimelzon A, Rosen JMStem cells (Dayton, Ohio)Transcriptional profiling of mammary gland side population cells. Stem Cells. 2006 Apr; 24(4):1065-74.Stem Cells2005-11-10T00:00:002005Transcriptional profiling of mammary gland side population cells.Authorship 103786116740736Cui Y, Parra I, Zhang M, Hilsenbeck SG, Tsimelzon A, Furukawa T, Horii A, Zhang ZY, Nicholson RI, Fuqua SACancer researchElevated expression of mitogen-activated protein kinase phosphatase 3 in breast tumors: a mechanism of tamoxifen resistance. Cancer Res. 2006 Jun 01; 66(11):5950-9.Cancer Res2006-06-01T00:00:002006Elevated expression of mitogen-activated protein kinase phosphatase 3 in breast tumors: a mechanism of tamoxifen resistance.Authorship 10389132014087Sevin BU, Ramos R, Gerhardt RT, Guerra L, Hilsenbeck S, Averette HEObstetrics and gynecologyComparative efficacy of short-term versus long-term cefoxitin prophylaxis against postoperative infection after radical hysterectomy: a prospective study. Obstet Gynecol. 1991 May; 77(5):729-34.Obstet Gynecol1991-05-01T00:00:001991Comparative efficacy of short-term versus long-term cefoxitin prophylaxis against postoperative infection after radical hysterectomy: a prospective study.17634277Redell MS, Tsimelzon A, Hilsenbeck SG, Tweardy DJJournal of leukocyte biologyConditional overexpression of Stat3alpha in differentiating myeloid cells results in neutrophil expansion and induces a distinct, antiapoptotic and pro-oncogenic gene expression pattern. J Leukoc Biol. 2007 Oct; 82(4):975-85.J Leukoc Biol2007-07-18T00:00:002007Conditional overexpression of Stat3alpha in differentiating myeloid cells results in neutrophil expansion and induces a distinct, antiapoptotic and pro-oncogenic gene expression pattern.17947490Li Y, Zhang Y, Hill J, Shen Q, Kim HT, Xu X, Hilsenbeck SG, Bissonnette RP, Lamph WW, Brown PHClinical cancer research : an official journal of the American Association for Cancer ResearchThe Rexinoid LG100268 prevents the development of preinvasive and invasive estrogen receptor negative tumors in MMTV-erbB2 mice. Clin Cancer Res. 2007 Oct 15; 13(20):6224-31.Clin Cancer Res2007-10-15T00:00:002007The Rexinoid LG100268 prevents the development of preinvasive and invasive estrogen receptor negative tumors in MMTV-erbB2 mice.18226176Rae JM, Skaar TC, Hilsenbeck SG, Oesterreich SBreast cancer research : BCRThe role of single nucleotide polymorphisms in breast cancer metastasis. Breast Cancer Res. 2008; 10(1):301.Breast Cancer Res2008-01-18T00:00:002008The role of single nucleotide polymorphisms in breast cancer metastasis.18270592Alten JA, Moran A, Tsimelzon AI, Mastrangelo MA, Hilsenbeck SG, Poli V, Tweardy DJPloS onePrevention of hypovolemic circulatory collapse by IL-6 activated Stat3. PLoS One. 2008 Feb 13; 3(2):e1605.PLoS One2008-02-13T00:00:002008Prevention of hypovolemic circulatory collapse by IL-6 activated Stat3.18425577Creighton CJ, Kent Osborne C, van de Vijver MJ, Foekens JA, Klijn JG, Horlings HM, Nuyten D, Wang Y, Zhang Y, Chamness GC, Hilsenbeck SG, Lee AV, Schiff RBreast cancer research and treatmentMolecular profiles of progesterone receptor loss in human breast tumors. Breast Cancer Res Treat. 2009 Mar; 114(2):287-99.Breast Cancer Res Treat2008-04-19T00:00:002008Molecular profiles of progesterone receptor loss in human breast tumors.18438108Blanchard DK, Shetty PB, Hilsenbeck SG, Elledge RMAnnals of surgeryAssociation of surgery with improved survival in stage IV breast cancer patients. Ann Surg. 2008 May; 247(5):732-8.Ann Surg2008-05-01T00:00:002008Association of surgery with improved survival in stage IV breast cancer patients.2121626Boike GM, Petru E, Sevin BU, Averette HE, Chou TC, Penalver M, Donato D, Schiano M, Hilsenbeck SG, Perras JGynecologic oncologyChemical enhancement of cisplatin cytotoxicity in a human ovarian and cervical cancer cell line. Gynecol Oncol. 1990 Sep; 38(3):315-22.Gynecol Oncol1990-09-01T00:00:001990Chemical enhancement of cisplatin cytotoxicity in a human ovarian and cervical cancer cell line.19375718Sweeney AD, Wu MF, Hilsenbeck SG, Brunicardi FC, Fisher WEThe Journal of surgical researchValue of pancreatic resection for cancer metastatic to the pancreas. J Surg Res. 2009 Oct; 156(2):189-98.J Surg Res2009-02-10T00:00:002009Value of pancreatic resection for cancer metastatic to the pancreas.20060482P?rez-Torres CJ, Massaad CA, Hilsenbeck SG, Serrano F, Pautler RGNeuroImageIn vitro and in vivo magnetic resonance imaging (MRI) detection of GFP through magnetization transfer contrast (MTC). Neuroimage. 2010 Apr 01; 50(2):375-82.Neuroimage2010-01-07T00:00:002010In vitro and in vivo magnetic resonance imaging (MRI) detection of GFP through magnetization transfer contrast (MTC).20569503Creighton CJ, Fu X, Hennessy BT, Casa AJ, Zhang Y, Gonzalez-Angulo AM, Lluch A, Gray JW, Brown PH, Hilsenbeck SG, Osborne CK, Mills GB, Lee AV, Schiff RBreast cancer research : BCRProteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer. Breast Cancer Res. 2010; 12(3):R40.Breast Cancer Res2010-06-22T00:00:002010Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer.20582464Rodriguez AA, Makris A, Wu MF, Rimawi M, Froehlich A, Dave B, Hilsenbeck SG, Chamness GC, Lewis MT, Dobrolecki LE, Jain D, Sahoo S, Osborne CK, Chang JCBreast cancer research and treatmentDNA repair signature is associated with anthracycline response in triple negative breast cancer patients. Breast Cancer Res Treat. 2010 Aug; 123(1):189-96.Breast Cancer Res Treat2010-06-26T00:00:002010DNA repair signature is associated with anthracycline response in triple negative breast cancer patients.20824048Toneff MJ, Du Z, Dong J, Huang J, Sinai P, Forman J, Hilsenbeck S, Schiff R, Huang S, Li YNeoplasia (New York, N.Y.)Somatic expression of PyMT or activated ErbB2 induces estrogen-independent mammary tumorigenesis. Neoplasia. 2010 Sep; 12(9):718-26.Neoplasia2010-09-01T00:00:002010Somatic expression of PyMT or activated ErbB2 induces estrogen-independent mammary tumorigenesis.20947521Hall CA, Wang R, Miao J, Oliva E, Shen X, Wheeler T, Hilsenbeck SG, Orsulic S, Goode SCancer researchHippo pathway effector Yap is an ovarian cancer oncogene. Cancer Res. 2010 Nov 01; 70(21):8517-25.Cancer Res2010-10-14T00:00:002010Hippo pathway effector Yap is an ovarian cancer oncogene.20980696Atkinson RL, Zhang M, Diagaradjane P, Peddibhotla S, Contreras A, Hilsenbeck SG, Woodward WA, Krishnan S, Chang JC, Rosen JMScience translational medicineThermal enhancement with optically activated gold nanoshells sensitizes breast cancer stem cells to radiation therapy. Sci Transl Med. 2010 Oct 27; 2(55):55ra79.Sci Transl Med2010-10-27T00:00:002010Thermal enhancement with optically activated gold nanoshells sensitizes breast cancer stem cells to radiation therapy.21135276Dave B, Migliaccio I, Gutierrez MC, Wu MF, Chamness GC, Wong H, Narasanna A, Chakrabarty A, Hilsenbeck SG, Huang J, Rimawi M, Schiff R, Arteaga C, Osborne CK, Chang JCJournal of clinical oncology : official journal of the American Society of Clinical OncologyLoss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers. J Clin Oncol. 2011 Jan 10; 29(2):166-73.J Clin Oncol2010-12-06T00:00:002010Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers.21459801Pathiraja TN, Shetty PB, Jelinek J, He R, Hartmaier R, Margossian AL, Hilsenbeck SG, Issa JP, Oesterreich SClinical cancer research : an official journal of the American Association for Cancer ResearchProgesterone receptor isoform-specific promoter methylation: association of PRA promoter methylation with worse outcome in breast cancer patients. Clin Cancer Res. 2011 Jun 15; 17(12):4177-86.Clin Cancer Res2011-04-01T00:00:002011Progesterone receptor isoform-specific promoter methylation: association of PRA promoter methylation with worse outcome in breast cancer patients.21633010Herschkowitz JI, Zhao W, Zhang M, Usary J, Murrow G, Edwards D, Knezevic J, Greene SB, Darr D, Troester MA, Hilsenbeck SG, Medina D, Perou CM, Rosen JMProceedings of the National Academy of Sciences of the United States of AmericaComparative oncogenomics identifies breast tumors enriched in functional tumor-initiating cells. Proc Natl Acad Sci U S A. 2012 Feb 21; 109(8):2778-83.Proc Natl Acad Sci U S A2011-06-01T00:00:002011Comparative oncogenomics identifies breast tumors enriched in functional tumor-initiating cells.2446489Sridhar KS, Varki J, Donnelly E, Davila E, Benedetto P, Hilsenbeck S, Thurer RJ, Rao RK, Fountzilas G, Beattie EJAmerican journal of clinical oncologyToxicity of FED chemotherapy in non-small-cell lung cancer. Am J Clin Oncol. 1987 Dec; 10(6):499-506.Am J Clin Oncol1987-12-01T00:00:001987Toxicity of FED chemotherapy in non-small-cell lung cancer.22157079Kessler JD, Kahle KT, Sun T, Meerbrey KL, Schlabach MR, Schmitt EM, Skinner SO, Xu Q, Li MZ, Hartman ZC, Rao M, Yu P, Dominguez-Vidana R, Liang AC, Solimini NL, Bernardi RJ, Yu B, Hsu T, Golding I, Luo J, Osborne CK, Creighton CJ, Hilsenbeck SG, Schiff R, Shaw CA, Elledge SJ, Westbrook TFScience (New York, N.Y.)A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis. Science. 2012 Jan 20; 335(6066):348-53.Science2011-12-08T00:00:002011A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis.Authorship 8789406Authorship 8812463Authorship 88448712Authorship 88517326Authorship 885439528541380Mo Q, Shen R, Guo C, Vannucci M, Chan KS, Hilsenbeck SGBiostatistics (Oxford, England)A fully Bayesian latent variable model for integrative clustering analysis of multi-type omics data. Biostatistics. 2018 01 01; 19(1):71-86.Biostatistics2018-01-01T00:00:002018A fully Bayesian latent variable model for integrative clustering analysis of multi-type omics data.28916657San Martin R, Pathak R, Jain A, Jung SY, Hilsenbeck SG, Pi?a-Barba MC, Sikora AG, Pienta KJ, Rowley DRCancer researchTenascin-C and Integrin a9 Mediate Interactions of Prostate Cancer with the Bone Microenvironment. Cancer Res. 2017 11 01; 77(21):5977-5988.Cancer Res2017-09-15T00:00:002017Tenascin-C and Integrin a9 Mediate Interactions of Prostate Cancer with the Bone Microenvironment.29128193Niravath P, Chen B, Chapman JW, Agarwal SK, Welschhans RL, Bongartz T, Kalari KR, Shepherd LE, Bartlett J, Pritchard K, Gelmon K, Hilsenbeck SG, Rimawi MF, Osborne CK, Goss PE, Ingle JNClinical breast cancerVitamin D Levels, Vitamin D Receptor Polymorphisms, and Inflammatory Cytokines in Aromatase Inhibitor-Induced Arthralgias: An Analysis of CCTG MA.27. Clin Breast Cancer. 2018 02; 18(1):78-87.Clin Breast Cancer2017-10-16T00:00:002017Vitamin D Levels, Vitamin D Receptor Polymorphisms, and Inflammatory Cytokines in Aromatase Inhibitor-Induced Arthralgias: An Analysis of CCTG MA.27.28839606Niravath P, Hayes T, Hilsenbeck SFrontline gastroenterologyUtility of screening for hepatocellular carcinoma among cirrhotics. Frontline Gastroenterol. 2011 Jul; 2(3):182-187.Frontline Gastroenterol2011-03-17T00:00:002011Utility of screening for hepatocellular carcinoma among cirrhotics.29578538Nair A, Chung HC, Sun T, Tyagi S, Dobrolecki LE, Dominguez-Vidana R, Kurley SJ, Orellana M, Renwick A, Henke DM, Katsonis P, Schmitt E, Chan DW, Li H, Mao S, Petrovic I, Creighton CJ, Gutierrez C, Dubrulle J, Stossi F, Tyner JW, Lichtarge O, Lin CY, Zhang B, Scott KL, Hilsenbeck SG, Sun J, Yu X, Osborne CK, Schiff R, Christensen JG, Shields DJ, Rimawi MF, Ellis MJ, Shaw CA, Lewis MT, Westbrook TFNature medicineCombinatorial inhibition of PTPN12-regulated receptors leads to a broadly effective therapeutic strategy in triple-negative breast cancer. Nat Med. 2018 05; 24(4):505-511.Nat Med2018-03-26T00:00:002018Combinatorial inhibition of PTPN12-regulated receptors leads to a broadly effective therapeutic strategy in triple-negative breast cancer.23633491Hartman ZC, Poage GM, den Hollander P, Tsimelzon A, Hill J, Panupinthu N, Zhang Y, Mazumdar A, Hilsenbeck SG, Mills GB, Brown PHCancer researchGrowth of triple-negative breast cancer cells relies upon coordinate autocrine expression of the proinflammatory cytokines IL-6 and IL-8. Cancer Res. 2013 Jun 01; 73(11):3470-80.Cancer Res2013-04-30T00:00:002013Growth of triple-negative breast cancer cells relies upon coordinate autocrine expression of the proinflammatory cytokines IL-6 and IL-8.2ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessorAuthorship 1025125Authorship 1076182D018719Chemicals & Drugs51925130.4861Receptor, ErbB-2Authorship 1084584D013629Chemicals & Drugs2378760.722061TamoxifenD001943Disorders1432156510.17611Breast Neoplasms30420638Neelakantan D, Zhou H, Oliphant MUJ, Zhang X, Simon LM, Henke DM, Shaw CA, Wu MF, Hilsenbeck SG, White LD, Lewis MT, Ford HLNature communicationsPublisher Correction: EMT cells increase breast cancer metastasis via paracrine GLI activation in neighbouring tumour cells. Nat Commun. 2018 11 12; 9(1):4720.Nat Commun2018-11-12T00:00:002018Publisher Correction: EMT cells increase breast cancer metastasis via paracrine GLI activation in neighbouring tumour cells.30401712Bu W, Liu Z, Jiang W, Nagi C, Huang S, Edwards DP, Jo E, Mo Q, Creighton CJ, Hilsenbeck SG, Leavitt AD, Lewis MT, Wong STC, Li YCancer researchMammary Precancerous Stem and Non-Stem Cells Evolve into Cancers of Distinct Subtypes. Cancer Res. 2019 01 01; 79(1):61-71.Cancer Res2018-11-06T00:00:002018Mammary Precancerous Stem and Non-Stem Cells Evolve into Cancers of Distinct Subtypes.Authorship 1079445Authorship 91433819Authorship 9224273Authorship 9241489Authorship 9286234Authorship 93133623Authorship 9332498Authorship 9336155Authorship 93413310Authorship 9348249Authorship 93700215Authorship 938637528730340Hertz DL, Kidwell KM, Hilsenbeck SG, Oesterreich S, Osborne CK, Philips S, Chenault C, Hartmaier RJ, Skaar TC, Sikora MJ, Rae JMBreast cancer research and treatmentCYP2D6 genotype is not associated with survival in breast cancer patients treated with tamoxifen: results from a population-based study. Breast Cancer Res Treat. 2017 Nov; 166(1):277-287.Breast Cancer Res Treat2017-07-20T00:00:002017CYP2D6 genotype is not associated with survival in breast cancer patients treated with tamoxifen: results from a population-based study.29110152Rimawi MF, De Angelis C, Contreras A, Pareja F, Geyer FC, Burke KA, Herrera S, Wang T, Mayer IA, Forero A, Nanda R, Goetz MP, Chang JC, Krop IE, Wolff AC, Pavlick AC, Fuqua SAW, Gutierrez C, Hilsenbeck SG, Li MM, Weigelt B, Reis-Filho JS, Kent Osborne C, Schiff RBreast cancer research and treatmentLow PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer. Breast Cancer Res Treat. 2018 02; 167(3):731-740.Breast Cancer Res Treat2017-11-07T00:00:002017Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer.29626114Chiang ACA, Fowler SW, Savjani RR, Hilsenbeck SG, Wallace CE, Cirrito JR, Das P, Jankowsky JLThe Journal of experimental medicineCombination anti-A? treatment maximizes cognitive recovery and rebalances mTOR signaling in APP mice. J Exp Med. 2018 05 07; 215(5):1349-1364.J Exp Med2018-04-06T00:00:002018Combination anti-A? treatment maximizes cognitive recovery and rebalances mTOR signaling in APP mice.29778097Johnston AN, Bu W, Hein S, Garcia S, Camacho L, Xue L, Qin L, Nagi C, Hilsenbeck SG, Kapali J, Podsypanina K, Nangia J, Li YBreast cancer research : BCRHyperprolactinemia-inducing antipsychotics increase breast cancer risk by activating JAK-STAT5 in precancerous lesions. Breast Cancer Res. 2018 05 19; 20(1):42.Breast Cancer Res2018-05-19T00:00:002018Hyperprolactinemia-inducing antipsychotics increase breast cancer risk by activating JAK-STAT5 in precancerous lesions.30482469Scollon S, Majumder MA, Bergstrom K, Wang T, McGuire AL, Robinson JO, Gutierrez AM, Lee CH, Hilsenbeck SG, Plon SE, Parsons DW, Street RLPatient education and counselingExome sequencing disclosures in pediatric cancer care: Patterns of communication among oncologists, genetic counselors, and parents. Patient Educ Couns. 2019 04; 102(4):680-686.Patient Educ Couns2018-11-12T00:00:002018Exome sequencing disclosures in pediatric cancer care: Patterns of communication among oncologists, genetic counselors, and parents.30488179Foster JH, Thompson PA, Bernhardt MB, Margolin JF, Hilsenbeck SG, Jo E, Marquez-Do DA, Scheurer ME, Schafer ESCancer chemotherapy and pharmacologyA prospective study of a simple algorithm to individually dose high-dose methotrexate for children with leukemia at risk for methotrexate toxicities. Cancer Chemother Pharmacol. 2019 02; 83(2):349-360.Cancer Chemother Pharmacol2018-11-28T00:00:002018A prospective study of a simple algorithm to individually dose high-dose methotrexate for children with leukemia at risk for methotrexate toxicities.30555156Nardone A, Weir H, Delpuech O, Brown H, De Angelis C, Cataldo ML, Fu X, Shea MJ, Mitchell T, Veeraraghavan J, Nagi C, Pilling M, Rimawi MF, Trivedi M, Hilsenbeck SG, Chamness GC, Jeselsohn R, Osborne CK, Schiff RBritish journal of cancerThe oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistance. Br J Cancer. 2019 02; 120(3):331-339.Br J Cancer2018-12-17T00:00:002018The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistance.30633903Xia J, Chiu LY, Nehring RB, Bravo N??ez MA, Mei Q, Perez M, Zhai Y, Fitzgerald DM, Pribis JP, Wang Y, Hu CW, Powell RT, LaBonte SA, Jalali A, Matadamas Guzm?n ML, Lentzsch AM, Szafran AT, Joshi MC, Richters M, Gibson JL, Frisch RL, Hastings PJ, Bates D, Queitsch C, Hilsenbeck SG, Coarfa C, Hu JC, Siegele DA, Scott KL, Liang H, Mancini MA, Herman C, Miller KM, Rosenberg SMCellBacteria-to-Human Protein Networks Reveal Origins of Endogenous DNA Damage. Cell. 2019 01 10; 176(1-2):127-143.e24.Cell2019-01-10T00:00:002019Bacteria-to-Human Protein Networks Reveal Origins of Endogenous DNA Damage.30537887Bielamowicz K, Okcu MF, Sonabend R, Paulino AC, Hilsenbeck SG, Dreyer Z, Suzawa H, Bryant R, Adesina A, Dauser R, Mahajan A, Chintagumpala MPediatric hematology and oncologyHypothyroidism after craniospinal irradiation with proton or photon therapy in patients with medulloblastoma. Pediatr Hematol Oncol. 2018 May; 35(4):257-267.Pediatr Hematol Oncol2018-12-11T00:00:002018Hypothyroidism after craniospinal irradiation with proton or photon therapy in patients with medulloblastoma.D011960Chemicals & Drugs44320840.566943Receptors, EstrogenAuthorship 1100223D018931Chemicals & Drugs2918400.662962Antineoplastic Agents, HormonalDepartment of MedicineBreast CenterDepartment of Molecular & Cellular BiologyMedicine-Hematology & OncologyBreast Cancer CenterMolecular & Cellular BiologyBaylor College of MedicineCHADCREIGHTONCHAD CREIGHTON0.000000000000000.000000000000001109CREIGHTON, CHADProfessorCARLOSRAMOSCARLOS RAMOS0.000000000000000.000000000000002089RAMOS, CARLOSProfessorJEFFREYROSENJEFFREY ROSEN0.000000000000000.000000000000002492ROSEN, JEFFREYDistinguished Service Professor3.188920.00190791155research areas3.173460.0113703225coauthor of99.572127.702460similar to11356selected publicationsCOSBORNEC OSBORNE29.71073630000000-95.396604500000003635OSBORNE, CDistinguished Service ProfessorRACHELSCHIFFRACHEL SCHIFF29.70508570000000-95.4018087000000098SCHIFF, RACHELProfessorMOTHAFFARRIMAWIMOTHAFFAR RIMAWI0.000000000000000.000000000000002107RIMAWI, MOTHAFFARProfessorGEORGECARRUMGEORGE CARRUM0.000000000000000.000000000000002995CARRUM, GEORGEProfessorSUZANNEFUQUASUZANNE FUQUA0.000000000000000.000000000000003633FUQUA, SUZANNEProfessorAuthorship 9433411830903140Veeraraghavan J, De Angelis C, Mao R, Wang T, Herrera S, Pavlick AC, Contreras A, Nuciforo P, Mayer IA, Forero A, Nanda R, Goetz MP, Chang JC, Wolff AC, Krop IE, Fuqua SAW, Prat A, Hilsenbeck SG, Weigelt B, Reis-Filho JS, Gutierrez C, Osborne CK, Rimawi MF, Schiff RAnnals of oncology : official journal of the European Society for Medical OncologyA combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer. Ann Oncol. 2019 06 01; 30(6):927-933.Ann Oncol2019-06-01T00:00:002019A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer.Authorship 1107604Authorship 1062011Authorship 9459911431037288Prat A, Pascual T, De Angelis C, Gutierrez C, Llombart-Cussac A, Wang T, Cort?s J, Rexer B, Par? L, Forero A, Wolff AC, Morales S, Adamo B, Bras?-Maristany F, Vidal M, Veeraraghavan J, Krop I, Galv?n P, Pavlick AC, Bermejo B, Izquierdo M, Rodrik-Outmezguine V, Reis-Filho JS, Hilsenbeck SG, Oliveira M, Dieci MV, Griguolo G, Fasani R, Nuciforo P, Parker JS, Conte P, Schiff R, Guarneri V, Osborne CK, Rimawi MFJournal of the National Cancer InstituteHER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade. J Natl Cancer Inst. 2020 01 01; 112(1):46-54.J Natl Cancer Inst2020-01-01T00:00:002020HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade.Authorship 1286104Authorship 12873721Authorship 128947423737486Zhang X, Claerhout S, Prat A, Dobrolecki LE, Petrovic I, Lai Q, Landis MD, Wiechmann L, Schiff R, Giuliano M, Wong H, Fuqua SW, Contreras A, Gutierrez C, Huang J, Mao S, Pavlick AC, Froehlich AM, Wu MF, Tsimelzon A, Hilsenbeck SG, Chen ES, Zuloaga P, Shaw CA, Rimawi MF, Perou CM, Mills GB, Chang JC, Lewis MTCancer researchA renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models. Cancer Res. 2013 Aug 01; 73(15):4885-97.Cancer Res2013-06-04T00:00:002013A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models.23883229Ortiz-Perez T, Trevino EJ, Sepulveda KA, Hilsenbeck SG, Wang T, Sedgwick ELAJR. American journal of roentgenologyDoes formal instruction about the BI-RADS ultrasound lexicon result in improved appropriate use of the lexicon? AJR Am J Roentgenol. 2013 Aug; 201(2):456-61.AJR Am J Roentgenol2013-08-01T00:00:002013Does formal instruction about the BI-RADS ultrasound lexicon result in improved appropriate use of the lexicon?24169421Robinson JO, Slashinski MJ, Wang T, Hilsenbeck SG, McGuire ALJournal of empirical research on human research ethics : JERHREParticipants' recall and understanding of genomic research and large-scale data sharing. J Empir Res Hum Res Ethics. 2013 Oct; 8(4):42-52.J Empir Res Hum Res Ethics2013-10-01T00:00:002013Participants' recall and understanding of genomic research and large-scale data sharing.Authorship 9495992Authorship 9496211531218477Niravath P, Hilsenbeck SG, Wang T, Jiralerspong S, Nangia J, Pavlick A, Ademuyiwa F, Frith A, Ma C, Park H, Rigden C, Suresh R, Ellis M, Kent Osborne C, Rimawi MFBreast cancer research and treatmentRandomized controlled trial of high-dose versus standard-dose vitamin D3 for prevention of aromatase inhibitor-induced arthralgia. Breast Cancer Res Treat. 2019 Sep; 177(2):427-435.Breast Cancer Res Treat2019-06-19T00:00:002019Randomized controlled trial of high-dose versus standard-dose vitamin D3 for prevention of aromatase inhibitor-induced arthralgia.31219523Lupo PJ, Schraw JM, Desrosiers TA, Nembhard WN, Langlois PH, Canfield MA, Copeland G, Meyer RE, Brown AL, Chambers TM, Sok P, Danysh HE, Carozza SE, Sisoudiya SD, Hilsenbeck SG, Janitz AE, Oster ME, Scheuerle AE, Schiffman JD, Luo C, Mian A, Mueller BA, Huff CD, Rasmussen SA, Scheurer ME, Plon SEJAMA oncologyAssociation Between Birth Defects and Cancer Risk Among Children and Adolescents in a Population-Based Assessment of 10 Million Live Births. JAMA Oncol. 2019 Aug 01; 5(8):1150-1158.JAMA Oncol2019-08-01T00:00:002019Association Between Birth Defects and Cancer Risk Among Children and Adolescents in a Population-Based Assessment of 10 Million Live Births.Authorship 9539631931420371Sethunath V, Hu H, De Angelis C, Veeraraghavan J, Qin L, Wang N, Simon LM, Wang T, Fu X, Nardone A, Pereira R, Nanda S, Griffith OL, Tsimelzon A, Shaw C, Chamness GC, Reis-Filho JS, Weigelt B, Heiser LM, Hilsenbeck SG, Huang S, Rimawi MF, Gray JW, Osborne CK, Schiff RMolecular cancer research : MCRTargeting the Mevalonate Pathway to Overcome Acquired Anti-HER2 Treatment Resistance in Breast Cancer. Mol Cancer Res. 2019 11; 17(11):2318-2330.Mol Cancer Res2019-08-16T00:00:002019Targeting the Mevalonate Pathway to Overcome Acquired Anti-HER2 Treatment Resistance in Breast Cancer.Authorship 1124062Authorship 1125331Authorship 9578961431653641De Angelis C, Nagi C, Hoyt CC, Liu L, Roman K, Wang C, Zheng Y, Veeraraghavan J, Sethunath V, Nuciforo P, Wang T, Tsimelzon A, Mao S, Hilsenbeck SG, Trivedi MV, Cataldo ML, Pavlick A, Wolff AC, Weigelt B, Reis-Filho JS, Prat A, Gutierrez C, Osborne CK, Rimawi MF, Schiff RClinical cancer research : an official journal of the American Association for Cancer ResearchEvaluation of the Predictive Role of Tumor Immune Infiltrate in Patients with HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2 Therapy without Chemotherapy. Clin Cancer Res. 2020 02 01; 26(3):738-745.Clin Cancer Res2019-10-25T00:00:002019Evaluation of the Predictive Role of Tumor Immune Infiltrate in Patients with HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2 Therapy without Chemotherapy.Authorship 95807018Authorship 9582271531672983Ochsner SA, Abraham D, Martin K, Ding W, McOwiti A, Kankanamge W, Wang Z, Andreano K, Hamilton RA, Chen Y, Hamilton A, Gantner ML, Dehart M, Qu S, Hilsenbeck SG, Becnel LB, Bridges D, Ma'ayan A, Huss JM, Stossi F, Foulds CE, Kralli A, McDonnell DP, McKenna NJScientific dataThe Signaling Pathways Project, an integrated 'omics knowledgebase for mammalian cellular signaling pathways. Sci Data. 2019 10 31; 6(1):252.Sci Data2019-10-31T00:00:002019The Signaling Pathways Project, an integrated 'omics knowledgebase for mammalian cellular signaling pathways.31662331Rimawi MF, Niravath P, Wang T, Rexer BN, Forero A, Wolff AC, Nanda R, Storniolo AM, Krop I, Goetz MP, Nangia JR, Jiralerspong S, Pavlick A, Veeraraghavan J, De Angelis C, Gutierrez C, Schiff R, Hilsenbeck SG, Osborne CK, Translational Breast Cancer Research ConsortiumClinical cancer research : an official journal of the American Association for Cancer ResearchTBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 versus 24 Weeks in Patients with HER2-Positive Breast Cancer. Clin Cancer Res. 2020 02 15; 26(4):821-827.Clin Cancer Res2019-10-29T00:00:002019TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 versus 24 Weeks in Patients with HER2-Positive Breast Cancer.true1ProfessorProfessorAuthorship 1086283true1Distinguished Service ProfessorDistinguished Service ProfessorSHIUH-RONGHOSHIUH-RONG HO0.000000000000000.000000000000006118HO, SHIUH-RONGFaculty Cliniciantrue1ProfessorProfessorAuthorship 1144124Authorship 9791255Authorship 9798702732142667Zheng ZY, Anurag M, Lei JT, Cao J, Singh P, Peng J, Kennedy H, Nguyen NC, Chen Y, Lavere P, Li J, Du XH, Cakar B, Song W, Kim BJ, Shi J, Seker S, Chan DW, Zhao GQ, Chen X, Banks KC, Lanman RB, Shafaee MN, Zhang XH, Vasaikar S, Zhang B, Hilsenbeck SG, Li W, Foulds CE, Ellis MJ, Chang ECCancer cellNeurofibromin Is an Estrogen Receptor-a Transcriptional Co-repressor in Breast Cancer. Cancer Cell. 2020 03 16; 37(3):387-402.e7.Cancer Cell2020-03-05T00:00:002020Neurofibromin Is an Estrogen Receptor-a Transcriptional Co-repressor in Breast Cancer.32165040Lau-Min K, Prakash P, Jo E, Thrift AP, Hilsenbeck S, Musher BLClinical colorectal cancerOutcomes Among Minority Patients With Metastatic Colorectal Cancer in a Safety-net Health Care System. Clin Colorectal Cancer. 2020 06; 19(2):e49-e57.Clin Colorectal Cancer2020-01-02T00:00:002020Outcomes Among Minority Patients With Metastatic Colorectal Cancer in a Safety-net Health Care System.Authorship 1149428Authorship 1160012Authorship 9883771232352029Elsarraj HS, Hong Y, Limback D, Zhao R, Berger J, Bishop SC, Sabbagh A, Oppenheimer L, Harper HE, Tsimelzon A, Huang S, Hilsenbeck SG, Edwards DP, Fontes J, Fan F, Madan R, Fangman B, Ellis A, Tawfik O, Persons DL, Fields T, Godwin AK, Hagan CR, Swenson-Fields K, Coarfa C, Thompson J, Behbod FNPJ breast cancerBCL9/STAT3 regulation of transcriptional enhancer networks promote DCIS progression. NPJ Breast Cancer. 2020; 6:12.NPJ Breast Cancer2020-04-24T00:00:002020BCL9/STAT3 regulation of transcriptional enhancer networks promote DCIS progression.Authorship 988912432383818Horne VE, Bielamowicz K, Nguyen J, Hilsenbeck S, Lindsay H, Sonabend R, Wood AC, Okcu F, Sisley SPediatric blood & cancerMethylphenidate improves weight control in childhood brain tumor survivors with hypothalamic obesity. Pediatr Blood Cancer. 2020 07; 67(7):e28379.Pediatr Blood Cancer2020-05-08T00:00:002020Methylphenidate improves weight control in childhood brain tumor survivors with hypothalamic obesity.Authorship 113602451Faculty ClinicianAuthorship 1114414Authorship 1167203Authorship 1168353Authorship 1136848Authorship 1137235Authorship 1171211Authorship 999500332923856Yuan Y, Lee JJ, Hilsenbeck SGJCO precision oncologyModel-Assisted Designs for Early-Phase Clinical Trials: Simplicity Meets Superiority. JCO Precis Oncol. 2019; 3.JCO Precis Oncol2019-10-24T00:00:002019Model-Assisted Designs for Early-Phase Clinical Trials: Simplicity Meets Superiority.Authorship 1184352Authorship 1003268333087164Montealegre JR, Anderson ML, Hilsenbeck SG, Chiao EY, Cantor SB, Parker SL, Daheri M, Bulsara S, Escobar B, Deshmukh AA, Jibaja-Weiss ML, Zare M, Scheurer METrialsMailed self-sample HPV testing kits to improve cervical cancer screening in a safety net health system: protocol for a hybrid effectiveness-implementation randomized controlled trial. Trials. 2020 Oct 21; 21(1):872.Trials2020-10-21T00:00:002020Mailed self-sample HPV testing kits to improve cervical cancer screening in a safety net health system: protocol for a hybrid effectiveness-implementation randomized controlled trial.true1ProfessorProfessortrue1ProfessorProfessorAuthorship 1129143Authorship 119531Authorship 10069571833323970Gu G, Tian L, Herzog SK, Rechoum Y, Gelsomino L, Gao M, Du L, Kim JA, Dustin D, Lo HC, Beyer AR, Edwards DG, Gonzalez T, Tsimelzon A, Huang HJ, Fernandez NM, Grimm SL, Hilsenbeck SG, Liu D, Xu J, Alaniz A, Li S, Mills GB, Janku F, Kittler R, Zhang XH, Coarfa C, Foulds CE, Symmans WF, And? S, Fuqua SAWOncogeneHormonal modulation of ESR1 mutant metastasis. Oncogene. 2021 02; 40(5):997-1011.Oncogene2020-12-15T00:00:002020Hormonal modulation of ESR1 mutant metastasis.Authorship 101056311Authorship 10106411633536276De Angelis C, Fu X, Cataldo ML, Nardone A, Pereira R, Veeraraghavan J, Nanda S, Qin L, Sethunath V, Wang T, Hilsenbeck SG, Benelli M, Migliaccio I, Guarducci C, Malorni L, Litchfield LM, Liu J, Donaldson J, Selenica P, Brown DN, Weigelt B, Reis-Filho JS, Park BH, Hurvitz SA, Slamon DJ, Rimawi MF, Jansen VM, Jeselsohn R, Osborne CK, Schiff RClinical cancer research : an official journal of the American Association for Cancer ResearchActivation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer. Clin Cancer Res. 2021 09 01; 27(17):4870-4882.Clin Cancer Res2021-02-03T00:00:002021Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer.33542078Wang X, Veeraraghavan J, Liu CC, Cao X, Qin L, Kim JA, Tan Y, Loo SK, Hu Y, Lin L, Lee S, Shea MJ, Mitchell T, Li S, Ellis MJ, Hilsenbeck SG, Schiff R, Wang XSClinical cancer research : an official journal of the American Association for Cancer ResearchTherapeutic Targeting of Nemo-like Kinase in Primary and Acquired Endocrine-resistant Breast Cancer. Clin Cancer Res. 2021 05 01; 27(9):2648-2662.Clin Cancer Res2021-02-04T00:00:002021Therapeutic Targeting of Nemo-like Kinase in Primary and Acquired Endocrine-resistant Breast Cancer.Authorship 1211206Authorship 1165021Authorship 1147351Authorship 11664910Authorship 10195131834045483Veeraraghavan J, Gutierrez C, Sethunath V, Mehravaran S, Giuliano M, Shea MJ, Mitchell T, Wang T, Nanda S, Pereira R, Davis R, Goutsouliak K, Qin L, De Angelis C, Diala I, Lalani AS, Nagi C, Hilsenbeck SG, Rimawi MF, Osborne CK, Schiff RNPJ breast cancerNeratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models. NPJ Breast Cancer. 2021 May 27; 7(1):63.NPJ Breast Cancer2021-05-27T00:00:002021Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models.Authorship 10206401334099494Yue F, Jiang W, Ku AT, Young AIJ, Zhang W, Souto EP, Gao Y, Yu Z, Wang Y, Creighton CJ, Nagi C, Wang T, Hilsenbeck SG, Feng XH, Huang S, Coarfa C, Zhang XH, Liu Q, Lin X, Li YCancer researchA Wnt-Independent LGR4-EGFR Signaling Axis in Cancer Metastasis. Cancer Res. 2021 09 01; 81(17):4441-4454.Cancer Res2021-06-07T00:00:002021A Wnt-Independent LGR4-EGFR Signaling Axis in Cancer Metastasis.Authorship 115722324122835Fan Y, Ge N, Wang X, Sun W, Mao R, Bu W, Creighton CJ, Zheng P, Vasudevan S, An L, Yang J, Zhao YJ, Zhang H, Li XN, Rao PH, Leung E, Lu YJ, Gray JW, Schiff R, Hilsenbeck SG, Osborne CK, Yang J, Zhang HThe Journal of pathologyAmplification and over-expression of MAP3K3 gene in human breast cancer promotes formation and survival of breast cancer cells. J Pathol. 2014 Jan; 232(1):75-86.J Pathol2014-01-01T00:00:002014Amplification and over-expression of MAP3K3 gene in human breast cancer promotes formation and survival of breast cancer cells.Authorship 10262481034312215Von Hoff DD, Clark GM, Coltman CA, Disis ML, Eckhardt SG, Ellis LM, Foti M, Garrett-Mayer E, G?nen M, Hidalgo M, Hilsenbeck SG, Littlefield JH, LoRusso PM, Lyerly HK, Meropol NJ, Patel JD, Piantadosi S, Post DA, Regan MM, Shyr Y, Tempero MA, Tepper JE, Von Roenn J, Weiner LM, Young DC, Vu NVClinical cancer research : an official journal of the American Association for Cancer ResearchA Grant-Based Experiment to Train Clinical Investigators: The AACR/ASCO Methods in Clinical Cancer Research Workshop. Clin Cancer Res. 2021 10 15; 27(20):5472-5481.Clin Cancer Res2021-07-26T00:00:002021A Grant-Based Experiment to Train Clinical Investigators: The AACR/ASCO Methods in Clinical Cancer Research Workshop.true1Distinguished Service ProfessorDistinguished Service ProfessorAuthorship 10288681134470810De Angelis C, Fu X, Cataldo ML, Nardone A, Pereira R, Veeraraghavan J, Nanda S, Qin L, Sethunath V, Wang T, Hilsenbeck SG, Benelli M, Migliaccio I, Guarducci C, Malorni L, Litchfield LM, Liu J, Donaldson J, Selenica P, Brown DN, Weigelt B, Reis-Filho JS, Park BH, Hurvitz SA, Slamon DJ, Rimawi MF, Jansen VM, Jeselsohn R, Osborne CK, Schiff RClinical cancer research : an official journal of the American Association for Cancer ResearchCorrection: Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer. Clin Cancer Res. 2021 Sep 01; 27(17):4939.Clin Cancer Res2021-09-01T00:00:002021Correction: Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer.Authorship 1174586Authorship 1280011Authorship 1031772834667127Young A, Bu W, Jiang W, Ku A, Kapali J, Dhamne S, Qin L, Hilsenbeck SG, Du YN, Li YCancer prevention research (Philadelphia, Pa.)Targeting the Pro-survival Protein BCL-2 to Prevent Breast Cancer. Cancer Prev Res (Phila). 2022 01; 15(1):3-10.Cancer Prev Res (Phila)2021-10-19T00:00:002021Targeting the Pro-survival Protein BCL-2 to Prevent Breast Cancer.Authorship 1167634Authorship 10326973134714554Hong Y, Limback D, Elsarraj HS, Harper H, Haines H, Hansford H, Ricci M, Kaufman C, Wedlock E, Xu M, Zhang J, May L, Cusick T, Inciardi M, Redick M, Gatewood J, Winblad O, Aripoli A, Huppe A, Balanoff C, Wagner JL, Amin AL, Larson KE, Ricci L, Tawfik O, Razek H, Meierotto RO, Madan R, Godwin AK, Thompson J, Hilsenbeck SG, Futreal A, Thompson A, Hwang ES, Fan F, Behbod F, Grand Challenge PRECISION ConsortiumThe Journal of pathologyMouse-INtraDuctal (MIND): an in vivo model for studying the underlying mechanisms of DCIS malignancy. J Pathol. 2022 02; 256(2):186-201.J Pathol2021-12-13T00:00:002021Mouse-INtraDuctal (MIND): an in vivo model for studying the underlying mechanisms of DCIS malignancy.Authorship 10342081834782721Gu G, Tian L, Herzog SK, Rechoum Y, Gelsomino L, Gao M, Du L, Kim JA, Dustin D, Lo HC, Beyer AR, Edwards DG, Gonzalez T, Tsimelzon A, Huang HJ, Fernandez NM, Grimm SL, Hilsenbeck SG, Liu D, Xu J, Alaniz A, Li S, Mills GB, Janku F, Kittler R, Zhang XH, Coarfa C, Foulds CE, Symmans WF, And? S, Fuqua SAWOncogeneCorrection to: Hormonal modulation of ESR1 mutant metastasis. Oncogene. 2022 Jan; 41(3):460.Oncogene2022-01-01T00:00:002022Correction to: Hormonal modulation of ESR1 mutant metastasis.Authorship 1337214Authorship 1175748Authorship 10398461335156101Gao Y, Kabotyanski EB, Shepherd JH, Villegas E, Acosta D, Hamor C, Sun T, Montmeyor-Garcia C, He X, Dobrolecki LE, Westbrook TF, Lewis MT, Hilsenbeck SG, Zhang XH, Perou CM, Rosen JMCancer research communicationsTumor suppressor PLK2 may serve as a biomarker in triple-negative breast cancer for improved response to PLK1 therapeutics. Cancer Res Commun. 2021 12; 1(3):178-193.Cancer Res Commun2021-12-27T00:00:002021Tumor suppressor PLK2 may serve as a biomarker in triple-negative breast cancer for improved response to PLK1 therapeutics.Authorship 1043725835410732Sapienza LG, Thomas JJ, Showalter TN, Echeverria AE, Ludwig MS, Chen AC, Jo E, Calsavara VF, Hilsenbeck SG, Jhingran A, Frumovitz MM, Baiocchi GGynecologic oncologyEndoscopic assessment of radiological stage IVA cervical cancer: A bivariate meta-analysis supporting an evidence-based staging algorithm proposal. Gynecol Oncol. 2022 06; 165(3):642-649.Gynecol Oncol2022-04-08T00:00:002022Endoscopic assessment of radiological stage IVA cervical cancer: A bivariate meta-analysis supporting an evidence-based staging algorithm proposal.Authorship 137796824097862Ding Y, He D, Florentin D, Frolov A, Hilsenbeck S, Ittmann M, Kadmon D, Miles B, Rowley D, Ayala GClinical cancer research : an official journal of the American Association for Cancer ResearchSemaphorin 4F as a critical regulator of neuroepithelial interactions and a biomarker of aggressive prostate cancer. Clin Cancer Res. 2013 Nov 15; 19(22):6101-11.Clin Cancer Res2013-10-04T00:00:002013Semaphorin 4F as a critical regulator of neuroepithelial interactions and a biomarker of aggressive prostate cancer.24381245Haricharan S, Dong J, Hein S, Reddy JP, Du Z, Toneff M, Holloway K, Hilsenbeck SG, Huang S, Atkinson R, Woodward W, Jindal S, Borges VF, Gutierrez C, Zhang H, Schedin PJ, Osborne CK, Tweardy DJ, Li YeLifeMechanism and preclinical prevention of increased breast cancer risk caused by pregnancy. Elife. 2013 Dec 31; 2:e00996.Elife2013-12-31T00:00:002013Mechanism and preclinical prevention of increased breast cancer risk caused by pregnancy.Authorship 1048900535726868Schafer ES, Chao K, Stevens AM, Jo E, Hilsenbeck SG, Gossai NP, Doan A, Colace SI, Guinipero T, Otterson D, Kaplan JA, Hinson A, Pommert L, Wayne AS, Bhojwani D, Burke MJPediatric blood & cancerReal-world experience in treating pediatric relapsed/refractory or therapy-related myeloid malignancies with decitabine, vorinostat, and FLAG therapy based on a phase 1 study run by the TACL consortium. Pediatr Blood Cancer. 2022 10; 69(10):e29812.Pediatr Blood Cancer2022-06-21T00:00:002022Real-world experience in treating pediatric relapsed/refractory or therapy-related myeloid malignancies with decitabine, vorinostat, and FLAG therapy based on a phase 1 study run by the TACL consortium.true1Faculty ClinicianFaculty ClinicianAuthorship 1215754Authorship 1216353Authorship 1217843Authorship 106203327Authorship 105784426Authorship 105649113Authorship 105452044Authorship 10608921236627285Echeverria GV, Cai S, Tu Y, Shao J, Powell E, Redwood AB, Jiang Y, McCoy A, Rinkenbaugh AL, Lau R, Trevarton AJ, Fu C, Gould R, Ravenberg EE, Huo L, Candelaria R, Santiago L, Adrada BE, Lane DL, Rauch GM, Yang WT, White JB, Chang JT, Moulder SL, Symmans WF, Hilsenbeck SG, Piwnica-Worms HNPJ breast cancerPredictors of success in establishing orthotopic patient-derived xenograft models of triple negative breast cancer. NPJ Breast Cancer. 2023 Jan 10; 9(1):2.NPJ Breast Cancer2023-01-10T00:00:002023Predictors of success in establishing orthotopic patient-derived xenograft models of triple negative breast cancer.36261627Lin M, Ku AT, Dong J, Yue F, Jiang W, Ibrahim AA, Peng F, Creighton CJ, Nagi C, Gutierrez C, Rosen JM, Zhang XH, Hilsenbeck SG, Chen X, Du YN, Huang S, Shi A, Fan Z, Li YOncogeneSTAT5 confers lactogenic properties in breast tumorigenesis and restricts metastatic potential. Oncogene. 2022 11; 41(48):5214-5222.Oncogene2022-10-19T00:00:002022STAT5 confers lactogenic properties in breast tumorigenesis and restricts metastatic potential.36469573Lee HS, Jang HJ, Ramineni M, Wang DY, Ramos D, Choi JM, Splawn T, Espinoza M, Almarez M, Hosey L, Jo E, Hilsenbeck S, Amos CI, Ripley RT, Burt BMClinical cancer research : an official journal of the American Association for Cancer ResearchA Phase II Window of Opportunity Study of Neoadjuvant PD-L1 versus PD-L1 plus CTLA-4 Blockade for Patients with Malignant Pleural Mesothelioma. Clin Cancer Res. 2023 02 01; 29(3):548-559.Clin Cancer Res2023-02-01T00:00:002023A Phase II Window of Opportunity Study of Neoadjuvant PD-L1 versus PD-L1 plus CTLA-4 Blockade for Patients with Malignant Pleural Mesothelioma.36585450Garcia-Recio S, Hinoue T, Wheeler GL, Kelly BJ, Garrido-Castro AC, Pascual T, De Cubas AA, Xia Y, Felsheim BM, McClure MB, Rajkovic A, Karaesmen E, Smith MA, Fan C, Ericsson PIG, Sanders ME, Creighton CJ, Bowen J, Leraas K, Burns RT, Coppens S, Wheless A, Rezk S, Garrett AL, Parker JS, Foy KK, Shen H, Park BH, Krop I, Anders C, Gastier-Foster J, Rimawi MF, Nanda R, Lin NU, Isaacs C, Marcom PK, Storniolo AM, Couch FJ, Chandran U, Davis M, Silverstein J, Ropelewski A, Liu MC, Hilsenbeck SG, Norton L, Richardson AL, Symmans WF, Wolff AC, Davidson NE, Carey LA, Lee AV, Balko JM, Hoadley KA, Laird PW, Mardis ER, King TA, AURORA US Network, Perou CMNature cancerMultiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis. Nat Cancer. 2023 01; 4(1):128-147.Nat Cancer2022-12-30T00:00:002022Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis.36619972Petrosyan V, Dobrolecki LE, Thistlethwaite L, Lewis AN, Sallas C, Srinivasan RR, Lei JT, Kovacevic V, Obradovic P, Ellis MJ, Osborne CK, Rimawi MF, Pavlick A, Shafaee MN, Dowst H, Jain A, Saltzman AB, Malovannaya A, Marangoni E, Welm AL, Welm BE, Li S, Wulf GM, Sonzogni O, Huang C, Vasaikar S, Hilsenbeck SG, Zhang B, Milosavljevic A, Lewis MTiScienceIdentifying biomarkers of differential chemotherapy response in TNBC patient-derived xenografts with a CTD/WGCNA approach. iScience. 2023 Jan 20; 26(1):105799.iScience2022-12-12T00:00:002022Identifying biomarkers of differential chemotherapy response in TNBC patient-derived xenografts with a CTD/WGCNA approach.Twitter @mfrimawiAuthorship 1214002Authorship 10645412036831684Stevens AM, Schafer ES, Li M, Terrell M, Rashid R, Paek H, Bernhardt MB, Weisnicht A, Smith WT, Keogh NJ, Alozie MC, Oviedo HH, Gonzalez AK, Ilangovan T, Mangubat-Medina A, Wang H, Jo E, Rabik CA, Bocchini C, Hilsenbeck S, Ball ZT, Cooper TM, Redell MSCancersRepurposing Atovaquone as a Therapeutic against Acute Myeloid Leukemia (AML): Combination with Conventional Chemotherapy Is Feasible and Well Tolerated. Cancers (Basel). 2023 Feb 20; 15(4).Cancers (Basel)2023-02-20T00:00:002023Repurposing Atovaquone as a Therapeutic against Acute Myeloid Leukemia (AML): Combination with Conventional Chemotherapy Is Feasible and Well Tolerated.Authorship 125032Authorship 10698502337195235Veeraraghavan J, Gutierrez C, De Angelis C, Davis R, Wang T, Pascual T, Selenica P, Sanchez K, Nitta H, Kapadia M, Pavlick AC, Galvan P, Rexer B, Forero-Torres A, Nanda R, Storniolo AM, Krop IE, Goetz MP, Nangia JR, Wolff AC, Weigelt B, Reis-Filho JS, Hilsenbeck SG, Prat A, Osborne CK, Schiff R, Rimawi MFClinical cancer research : an official journal of the American Association for Cancer ResearchA Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2+ Breast Cancer. Clin Cancer Res. 2023 08 15; 29(16):3101-3109.Clin Cancer Res2023-08-15T00:00:002023A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2+ Breast Cancer.Authorship 122592Authorship 123756Authorship 10756561737501682Kim BJ, Zheng ZY, Lei JT, Holt MV, Chen A, Peng J, Fandino D, Singh P, Kennedy H, Dou Y, Chica-Parrado MDR, Bikorimana E, Ye D, Wang Y, Hanker AB, Mohamed N, Hilsenbeck SG, Lim B, Asirvatham JR, Sreekumar A, Zhang B, Miles G, Anurag M, Ellis MJ, Chang ECCancer research communicationsProteogenomic Approaches for the Identification of NF1/Neurofibromin-depleted Estrogen Receptor-positive Breast Cancers for Targeted Treatment. Cancer Res Commun. 2023 07; 3(7):1366-1377.Cancer Res Commun2023-07-26T00:00:002023Proteogenomic Approaches for the Identification of NF1/Neurofibromin-depleted Estrogen Receptor-positive Breast Cancers for Targeted Treatment.Authorship 137834Authorship 10788241037562095Kemnade JO, Florez M, Sabichi A, Zhang J, Jhaveri P, Chen G, Chen A, Miller-Chism C, Shaun B, Hilsenbeck SG, Hernandez DJ, Skinner HD, Sandulache VCOral oncologyPhase I / II trial of metformin as a chemo-radiosensitizer in a head and neck cancer patient population. Oral Oncol. 2023 10; 145:106536.Oral Oncol2023-08-08T00:00:002023Phase I / II trial of metformin as a chemo-radiosensitizer in a head and neck cancer patient population.Authorship 10809601837808840Zhao N, Kabotyanski EB, Saltzman AB, Malovannaya A, Yuan X, Reineke LC, Lieu N, Gao Y, Pedroza DA, Calderon SJ, Smith AJ, Hamor C, Safari K, Savage S, Zhang B, Zhou J, Solis LM, Hilsenbeck SG, Fan C, Perou CM, Rosen JMbioRxiv : the preprint server for biologyTargeting EIF4A triggers an interferon response to synergize with chemotherapy and suppress triple-negative breast cancer. bioRxiv. 2023 Sep 28.bioRxiv2023-09-28T00:00:002023Targeting EIF4A triggers an interferon response to synergize with chemotherapy and suppress triple-negative breast cancer.Authorship 10826741837874652Zhao N, Kabotyanski EB, Saltzman AB, Malovannaya A, Yuan X, Reineke LC, Lieu N, Gao Y, Pedroza DA, Calderon SJ, Smith AJ, Hamor C, Safari K, Savage S, Zhang B, Zhou J, Solis LM, Hilsenbeck SG, Fan C, Perou CM, Rosen JMThe Journal of clinical investigationTargeting eIF4A triggers an interferon response to synergize with chemotherapy and suppress triple-negative breast cancer. J Clin Invest. 2023 Dec 15; 133(24).J Clin Invest2023-12-15T00:00:002023Targeting eIF4A triggers an interferon response to synergize with chemotherapy and suppress triple-negative breast cancer.Authorship 1083093637935320Parker SL, Amboree TL, Bulsara S, Daheri M, Anderson ML, Hilsenbeck SG, Jibaja-Weiss ML, Zare M, Schmeler KM, Deshmukh AA, Chiao EY, Scheurer ME, Montealegre JRAmerican journal of preventive medicineSelf-Sampling for Human Papillomavirus Testing: Acceptability in a U.S. Safety Net Health System. Am J Prev Med. 2024 Mar; 66(3):540-547.Am J Prev Med2023-11-05T00:00:002023Self-Sampling for Human Papillomavirus Testing: Acceptability in a U.S. Safety Net Health System.Authorship 149805Authorship 150764Authorship 142124Authorship 158203Authorship 183695Authorship 184375Authorship 188459Authorship 188874Authorship 1088584938317231Qian J, Ma Y, Tahaney WM, Moyer CL, Lanier A, Hill J, Coleman D, Koupaei N, Hilsenbeck SG, Savage MI, Page BDG, Mazumdar A, Brown PHBreast cancer research : BCRThe novel phosphatase NUDT5 is a critical regulator of triple-negative breast cancer growth. Breast Cancer Res. 2024 02 05; 26(1):23.Breast Cancer Res2024-02-05T00:00:002024The novel phosphatase NUDT5 is a critical regulator of triple-negative breast cancer growth.true1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessorAuthorship 175554Authorship 196952Authorship 199386Authorship 19966Authorship 20784Authorship 244925Authorship 182551Authorship 22393Authorship 195529Authorship 28075Authorship 285279Authorship 242794Authorship 245043Authorship 2497311Authorship 256081Authorship 232285Authorship 23399Authorship 234589Authorship 1390343Authorship 13903510Authorship 1390367Authorship 1390372Authorship 13903820Authorship 1390395Authorship 1390409Authorship 1390419Authorship 1390426Authorship 139043524616359Burstein MD, Robinson JO, Hilsenbeck SG, McGuire AL, Lau CCPediatricsPediatric data sharing in genomic research: attitudes and preferences of parents. Pediatrics. 2014 Apr; 133(4):690-7.Pediatrics2014-03-10T00:00:002014Pediatric data sharing in genomic research: attitudes and preferences of parents.24569375Shan M, You R, Yuan X, Frazier MV, Porter P, Seryshev A, Hong JS, Song LZ, Zhang Y, Hilsenbeck S, Whitehead L, Zarinkamar N, Perusich S, Corry DB, Kheradmand FThe Journal of clinical investigationAgonistic induction of PPAR? reverses cigarette smoke-induced emphysema. J Clin Invest. 2014 Mar; 124(3):1371-81.J Clin Invest2014-02-24T00:00:002014Agonistic induction of PPAR? reverses cigarette smoke-induced emphysema.24395789Hatcher RJ, Dong J, Liu S, Bian G, Contreras A, Wang T, Hilsenbeck SG, Li Y, Zhang PProceedings of the National Academy of Sciences of the United States of AmericaPttg1/securin is required for the branching morphogenesis of the mammary gland and suppresses mammary tumorigenesis. Proc Natl Acad Sci U S A. 2014 Jan 21; 111(3):1008-13.Proc Natl Acad Sci U S A2014-01-06T00:00:002014Pttg1/securin is required for the branching morphogenesis of the mammary gland and suppresses mammary tumorigenesis.24374933Parikh N, Hilsenbeck S, Creighton CJ, Dayaram T, Shuck R, Shinbrot E, Xi L, Gibbs RA, Wheeler DA, Donehower LAThe Journal of pathologyEffects of TP53 mutational status on gene expression patterns across 10 human cancer types. J Pathol. 2014 Apr; 232(5):522-33.J Pathol2014-01-29T00:00:002014Effects of TP53 mutational status on gene expression patterns across 10 human cancer types.24077732Covington KR, Brusco L, Barone I, Tsimelzon A, Selever J, Corona-Rodriguez A, Brown P, Kumar R, Hilsenbeck SG, Fuqua SABreast cancer research and treatmentMetastasis tumor-associated protein 2 enhances metastatic behavior and is associated with poor outcomes in estrogen receptor-negative breast cancer. Breast Cancer Res Treat. 2013 Oct; 141(3):375-384.Breast Cancer Res Treat2013-09-28T00:00:002013Metastasis tumor-associated protein 2 enhances metastatic behavior and is associated with poor outcomes in estrogen receptor-negative breast cancer.24008095Atkinson RL, Yang WT, Rosen DG, Landis MD, Wong H, Lewis MT, Creighton CJ, Sexton KR, Hilsenbeck SG, Sahin AA, Brewster AM, Woodward WA, Chang JCBreast cancer research : BCRCancer stem cell markers are enriched in normal tissue adjacent to triple negative breast cancer and inversely correlated with DNA repair deficiency. Breast Cancer Res. 2013; 15(5):R77.Breast Cancer Res2013-01-01T00:00:002013Cancer stem cell markers are enriched in normal tissue adjacent to triple negative breast cancer and inversely correlated with DNA repair deficiency.8536466Martinez AJ, Mills MB, Jaceldo KB, Tio FO, Aigbivbalu IB, Hilsenbeck SB, Yee RWCorneaStandardization of conjunctival impression cytology. Cornea. 1995 Sep; 14(5):515-22.Cornea1995-09-01T00:00:001995Standardization of conjunctival impression cytology.Authorship 351942Authorship 248324Authorship 257775Authorship 269204Authorship 381954Authorship 385282Authorship 393894Authorship 276605Authorship 2894214Authorship 277412Authorship 415982Authorship 287195Authorship 296812Authorship 454935Authorship 329885Authorship 331628Authorship 471845Authorship 3348710Authorship 488003Authorship 36803Authorship 524994Authorship 373219Authorship 536991Authorship 559764Authorship 564393Authorship 404433Authorship 393346Authorship 575232Authorship 588456Authorship 147059624874954Feng Q, Zhang Z, Shea MJ, Creighton CJ, Coarfa C, Hilsenbeck SG, Lanz R, He B, Wang L, Fu X, Nardone A, Song Y, Bradner J, Mitsiades N, Mitsiades CS, Osborne CK, Schiff R, O'Malley BWCell researchAn epigenomic approach to therapy for tamoxifen-resistant breast cancer. Cell Res. 2014 Jul; 24(7):809-19.Cell Res2014-05-30T00:00:002014An epigenomic approach to therapy for tamoxifen-resistant breast cancer.Authorship 60062Authorship 606542Authorship 431614Authorship 614691Authorship 623006Authorship 448744Authorship 457793Authorship 473948Authorship 464113Authorship 492207Authorship 510717Authorship 511083Authorship 1475451125099679Veeraraghavan J, Tan Y, Cao XX, Kim JA, Wang X, Chamness GC, Maiti SN, Cooper LJ, Edwards DP, Contreras A, Hilsenbeck SG, Chang EC, Schiff R, Wang XSNature communicationsRecurrent ESR1-CCDC170 rearrangements in an aggressive subset of oestrogen receptor-positive breast cancers. Nat Commun. 2014 Aug 07; 5:4577.Nat Commun2014-08-07T00:00:002014Recurrent ESR1-CCDC170 rearrangements in an aggressive subset of oestrogen receptor-positive breast cancers.Authorship 714632Authorship 508575Authorship 1492239Authorship 1492246Authorship 149225924891218Wei W, Tweardy DJ, Zhang M, Zhang X, Landua J, Petrovic I, Bu W, Roarty K, Hilsenbeck SG, Rosen JM, Lewis MTStem cells (Dayton, Ohio)STAT3 signaling is activated preferentially in tumor-initiating cells in claudin-low models of human breast cancer. Stem Cells. 2014 Oct; 32(10):2571-82.Stem Cells2014-10-01T00:00:002014STAT3 signaling is activated preferentially in tumor-initiating cells in claudin-low models of human breast cancer.Authorship 516966Authorship 728453Authorship 531719Authorship 767363Authorship 553016Authorship 782743Authorship 797627Authorship 801826Authorship 805719Authorship 574002Authorship 578582Authorship 821696Authorship 826453Authorship 587373Authorship 831215Authorship 589404Authorship 5854019Authorship 605267Authorship 861084Authorship 15207926Authorship 152080925212826Fu X, Creighton CJ, Biswal NC, Kumar V, Shea M, Herrera S, Contreras A, Gutierrez C, Wang T, Nanda S, Giuliano M, Morrison G, Nardone A, Karlin KL, Westbrook TF, Heiser LM, Anur P, Spellman P, Guichard SM, Smith PD, Davies BR, Klinowska T, Lee AV, Mills GB, Rimawi MF, Hilsenbeck SG, Gray JW, Joshi A, Osborne CK, Schiff RBreast cancer research : BCROvercoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase. Breast Cancer Res. 2014 Sep 11; 16(5):430.Breast Cancer Res2014-09-11T00:00:002014Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase.25208879Burstein MD, Tsimelzon A, Poage GM, Covington KR, Contreras A, Fuqua SA, Savage MI, Osborne CK, Hilsenbeck SG, Chang JC, Mills GB, Lau CC, Brown PHClinical cancer research : an official journal of the American Association for Cancer ResearchComprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. Clin Cancer Res. 2015 Apr 01; 21(7):1688-98.Clin Cancer Res2014-09-10T00:00:002014Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer.Authorship 866782Authorship 1529076Authorship 153083525228531Arteaga CL, Adamson PC, Engelman JA, Foti M, Gaynor RB, Hilsenbeck SG, Limburg PJ, Lowe SW, Mardis ER, Ramsey S, Rebbeck TR, Richardson AL, Rubin EH, Weiner GJClinical cancer research : an official journal of the American Association for Cancer ResearchAACR Cancer Progress Report 2014. Clin Cancer Res. 2014 Oct 01; 20(19 Suppl):S1-S112.Clin Cancer Res2014-09-16T00:00:002014AACR Cancer Progress Report 2014.25317207Scollon S, Bergstrom K, Kerstein RA, Wang T, Hilsenbeck SG, Ramamurthy U, Gibbs RA, Eng CM, Chintagumpala MM, Berg SL, McCullough LB, McGuire AL, Plon SE, Parsons DWGenome medicineObtaining informed consent for clinical tumor and germline exome sequencing of newly diagnosed childhood cancer patients. Genome Med. 2014; 6(9):69.Genome Med2014-09-17T00:00:002014Obtaining informed consent for clinical tumor and germline exome sequencing of newly diagnosed childhood cancer patients.Authorship 894114Authorship 6549510Authorship 648025Authorship 648912Authorship 665832Authorship 936631Authorship 673483Authorship 97426Authorship 982585Authorship 712633Authorship 717543Authorship 702124Authorship 702559Authorship 746477Authorship 731856Authorship 753081Authorship 747203Authorship 153723625378456Niravath P, Tham YL, Wang T, Rodriguez A, Foreman C, Hilsenbeck SG, Elledge R, Rimawi MThe oncologistA phase II trial of capecitabine concomitantly with whole-brain radiotherapy followed by capecitabine and sunitinib for brain metastases from breast cancer. Oncologist. 2015 Jan; 20(1):13.Oncologist2014-11-06T00:00:002014A phase II trial of capecitabine concomitantly with whole-brain radiotherapy followed by capecitabine and sunitinib for brain metastases from breast cancer.Authorship 780203Authorship 781702Authorship 790282Authorship 779742Authorship 15529720Authorship 15543120